<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antifibrinolytics for heavy menstrual bleeding - Bryant‐Smith, AC - 2018 | Cochrane Library</title> <meta content="Antifibrinolytics for heavy menstrual bleeding - Bryant‐Smith, AC - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000249.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antifibrinolytics for heavy menstrual bleeding - Bryant‐Smith, AC - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000249.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000249.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antifibrinolytics for heavy menstrual bleeding" name="citation_title"/> <meta content="Alison C Bryant‐Smith" name="citation_author"/> <meta content="Guy's and St Thomas' NHS Foundation Trust" name="citation_author_institution"/> <meta content="dr.alison.bryantsmith@gmail.com" name="citation_author_email"/> <meta content="Anne Lethaby" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Martha Hickey" name="citation_author"/> <meta content="The Royal Women's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD000249.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/04/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000249.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000249.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000249.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; Antifibrinolytic Agents [*therapeutic use]; Ethamsylate [therapeutic use]; Hemostatics [therapeutic use]; Intrauterine Devices, Medicated; Lythraceae; Menorrhagia [*drug therapy]; Norethindrone [therapeutic use]; Plant Extracts [therapeutic use]; Progestins [therapeutic use]; Randomized Controlled Trials as Topic; Tranexamic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000249.pub2&amp;doi=10.1002/14651858.CD000249.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000249\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000249\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","th","ms","ja","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000249.pub2",title:"Antifibrinolytics for heavy menstrual bleeding",firstPublishedDate:"Apr 15, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000249.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000249.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000249.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000249.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000249.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000249.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000249.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000249.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000249.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000249.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10318 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000249.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-sec-0133"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-sec-0127"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/appendices#CD000249-sec-0138"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/table_n/CD000249StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/table_n/CD000249StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antifibrinolytics for heavy menstrual bleeding</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information#CD000249-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Alison C Bryant‐Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information#CD000249-cr-0003">Anne Lethaby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information#CD000249-cr-0004">Cindy Farquhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information#CD000249-cr-0005">Martha Hickey</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information/en#CD000249-sec-0152">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 April 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000249.pub2">https://doi.org/10.1002/14651858.CD000249.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000249-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000249-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000249-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000249-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD000249-abs-0002">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000249-abs-0001" lang="en"> <section id="CD000249-sec-0001"> <h3 class="title" id="CD000249-sec-0001">Background</h3> <p>Heavy menstrual bleeding (HMB) is an important physical and social problem for women. Oral treatment for HMB includes antifibrinolytic drugs, which are designed to reduce bleeding by inhibiting clot‐dissolving enzymes in the endometrium. </p> <p>Historically, there has been some concern that using the antifibrinolytic tranexamic acid (TXA) for HMB may increase the risk of venous thromboembolic disease. This is an umbrella term for deep venous thrombosis (blood clots in the blood vessels in the legs) and pulmonary emboli (blood clots in the blood vessels in the lungs). </p> </section> <section id="CD000249-sec-0002"> <h3 class="title" id="CD000249-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of antifibrinolytic medications as a treatment for heavy menstrual bleeding. </p> </section> <section id="CD000249-sec-0003"> <h3 class="title" id="CD000249-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO and two trials registers in November 2017, together with reference checking and contact with study authors and experts in the field. </p> </section> <section id="CD000249-sec-0004"> <h3 class="title" id="CD000249-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing antifibrinolytic agents versus placebo, no treatment or other medical treatment in women of reproductive age with HMB. Twelve studies utilised TXA and one utilised a prodrug of TXA (Kabi). </p> </section> <section id="CD000249-sec-0005"> <h3 class="title" id="CD000249-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. The primary review outcomes were menstrual blood loss (MBL), improvement in HMB, and thromboembolic events. </p> </section> <section id="CD000249-sec-0006"> <h3 class="title" id="CD000249-sec-0006">Main results</h3> <p>We included 13 RCTs (1312 participants analysed). The evidence was very low to moderate quality: the main limitations were risk of bias (associated with lack of blinding, and poor reporting of study methods), imprecision and inconsistency. </p> <p><b>Antifibrinolytics (TXA or Kabi) versus no treatment or placebo</b> </p> <p>When compared with a placebo, antifibrinolytics were associated with reduced mean blood loss (MD −53.20 mL per cycle, 95% CI −62.70 to −43.70; I² = 8%; 4 RCTs, participants = 565; moderate‐quality evidence) and higher rates of improvement (RR 3.34, 95% CI 1.84 to 6.09; 3 RCTS, participants = 271; moderate‐quality evidence). This suggests that if 11% of women improve without treatment, 43% to 63% of women taking antifibrinolytics will do so. There was no clear evidence of a difference between the groups in adverse events (RR 1.05, 95% CI 0.93 to 1.18; 1 RCT, participants = 297; low‐quality evidence). Only one thromboembolic event occurred in the two studies that reported this outcome. </p> <p><b>TXA versus progestogens</b> </p> <p>There was no clear evidence of a difference between the groups in mean blood loss measured using the Pictorial Blood Assessment Chart (PBAC) (MD −12.22 points per cycle, 95% CI −30.8 to 6.36; I² = 0%; 3 RCTs, participants = 312; very low quality evidence), but TXA was associated with a higher likelihood of improvement (RR 1.54, 95% CI 1.31 to 1.80; I² = 32%; 5 RCTs, participants = 422; low‐quality evidence). This suggests that if 46% of women improve with progestogens, 61% to 83% of women will do so with TXA. </p> <p>Adverse events were less common in the TXA group (RR 0.66, 95% CI 0.46 to 0.94; I² = 28%; 4 RCTs, participants = 349; low‐quality evidence). No thromboembolic events were reported in any group. </p> <p><b>TXA versus non‐steroidal anti‐inflammatory drugs (NSAIDs)</b> </p> <p>TXA was associated with reduced mean blood loss (MD −73.00 mL per cycle, 95% CI −123.35 to −22.65; 1 RCT, participants = 49; low‐quality evidence) and higher likelihood of improvement (RR 1.43, 95% CI 1.18 to 1.74; 1<sup>2</sup> = 0%; 2 RCTs, participants = 161; low‐quality evidence). This suggests that if 61% of women improve with NSAIDs, 71% to 100% of women will do so with TXA. Adverse events were uncommon and no comparative data were available. No thromboembolic events were reported. </p> <p><b>TXA versus ethamsylate</b> </p> <p>TXA was associated with reduced mean blood loss (MD 100 mL per cycle, 95% CI −141.82 to −58.18; 1 RCT, participants = 53; low‐quality evidence), but there was insufficient evidence to determine whether the groups differed in rates of improvement (RR 1.56, 95% CI 0.95 to 2.55; 1 RCT, participants = 53; very low quality evidence) or withdrawal due to adverse events (RR 0.78, 95% CI 0.19 to 3.15; 1 RCT, participants = 53; very low quality evidence). </p> <p><b>TXA versus herbal medicines (Safoof Habis and Punica granatum)</b> </p> <p>TXA was associated with a reduced mean PBAC score after three months' treatment (MD −23.90 pts per cycle, 95% CI −31.92 to −15.88; I² = 0%; 2 RCTs, participants = 121; low‐quality evidence). No data were available for rates of improvement. TXA was associated with a reduced mean PBAC score three months after the end of the treatment phase (MD −10.40 points per cycle, 95% CI −19.20 to −1.60; I² not applicable; 1 RCT, participants = 84; very low quality evidence). There was insufficient evidence to determine whether the groups differed in rates of adverse events (RR 2.25, 95% CI 0.74 to 6.80; 1 RCT, participants = 94; very low quality evidence). No thromboembolic events were reported. </p> <p><b>TXA versus levonorgestrel intrauterine system (LIUS)</b> </p> <p>TXA was associated with a higher median PBAC score than LIUS (median difference 125.5 points; 1 RCT, participants = 42; very low quality evidence) and a lower likelihood of improvement (RR 0.43, 95% CI 0.24 to 0.77; 1 RCT, participants = 42; very low quality evidence). This suggests that if 85% of women improve with LIUS, 20% to 65% of women will do so with TXA. There was insufficient evidence to determine whether the groups differed in rates of adverse events (RR 0.83, 95% CI 0.25 to 2.80; 1 RCT, participants = 42; very low quality evidence). No thromboembolic events were reported. </p> </section> <section id="CD000249-sec-0007"> <h3 class="title" id="CD000249-sec-0007">Authors' conclusions</h3> <p>Antifibrinolytic treatment (such as TXA) appears effective for treating HMB compared to placebo, NSAIDs, oral luteal progestogens, ethamsylate, or herbal remedies, but may be less effective than LIUS. There were too few data for most comparisons to determine whether antifibrinolytics were associated with increased risk of adverse events, and most studies did not specifically include thromboembolism as an outcome. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000249-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000249-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000249-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000249-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000249-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000249-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000249-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000249-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD000249-abs-0006">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000249-abs-0004" lang="en"> <h3>Antifibrinolytics (such as tranexamic acid) for treatment of heavy menstrual bleeding</h3> <p><b>Review question</b> </p> <p>Antifibrinolytic agents are designed to reduce bleeding by inhibiting endometrial clot‐dissolving enzymes (in the uterine lining); Cochrane researchers reviewed the evidence about the effect of these medications (such as tranexamic acid, TXA) versus placebo and other medical therapies in women with heavy menstrual bleeding (HMB: defined as more than 80 millilitres (&gt; 80 mL) of blood loss per menstrual cycle). </p> <p><b>Background</b> </p> <p>Antifibrinolytic agents (such as tranexamic acid, TXA) are commonly used to manage HMB. However, historically there has been concern that they may cause dangerous blood clots in the legs or lungs. There are a variety of other medications that can be used to treat HMB. We compared the benefits and risks of the treatments. </p> <p><b>Study characteristics</b> </p> <p>We found 13 randomized controlled trials (RCTs) comparing an antifibrinolytic medication with a different medical therapy, in a total of 1312 women with heavy menstrual bleeding. The evidence is current to November 2017. </p> <p><b>Key results</b> </p> <p>Antifibrinolytic medication may improve HMB in women aged 15 to 50 years old, without substantially increasing the rate of adverse events. Evidence suggests there is a 40% to 50% reduction in the amount of menstrual blood lost per menstrual cycle for participants taking TXA. Antifibrinolytic treatment was better at improving HMB loss than other medical treatments, except for the levonorgestrel intrauterine system (LIUS), a plastic device placed in the uterus which releases hormone to prevent conception. </p> <p>The evidence suggests that if 10.9% of women taking placebo report an improvement in HMB, 36.3% of women taking TXA will do so. </p> <p>TXA probably improves quality of life for women with HMB.</p> <p>We did not find any evidence that side effects (including life‐threatening blood clots) were increased in women taking antifibrinolytic treatment compared to placebo or other treatments for HMB. Two studies measured venous thromboembolic events: unfortunately these studies did not have enough participants to distinguish a real effect of a certain size from pure luck. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence was of very low to moderate quality. The main limitations were: risk of bias, due to participants/investigators being aware of which medication they were receiving (known as lack of blinding), or the study's methods not being reported very clearly; imprecision (i.e. repeated measurements being far apart from each other), and inconsistency (i.e. as the sample size increases, the sampling distribution becomes increasingly wide around the true parameter value). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000249-sec-0133" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000249-sec-0133"></div> <h3 class="title" id="CD000249-sec-0134">Implications for practice</h3> <section id="CD000249-sec-0134"> <p>Evidence suggests that antifibrinolytic treatment (such as TXA) is effective treatment with women of reproductive age with heavy menstrual bleeding: it is associated with a reduction in measured heavy menstrual bleeding when compared with placebo, NSAIDS, oral luteal progestogens, ethamsylate, or herbal remedies. On the other hand, LIUS showed a reduction in median PBAC scores compared to TXA. For some of these comparisons, differences between treatments were not always perceived by the women in the trials. These findings are based on small trials with variable quality. </p> <p>Oral administration of antifibrinolytic therapy (such as TXA) does not seem to be associated with any increase in major adverse events. Most studies did not include VTE as an end‐point; studies that did measure VTE have not shown any increase in risk with antifibrinolytic treatment, but were underpowered for this outcome. Hence, there was insufficient evidence to assess thromboembolism risk with antifibrinolytic treatment. </p> </section> <h3 class="title" id="CD000249-sec-0135">Implications for research</h3> <section id="CD000249-sec-0135"> <p>More information is needed on the comparative efficacy of antifibrinolytic treatment, compared to other medical therapies such as the combined oral contraceptive pill, LIUS, and progestogens taken for 21 days (or more) of the menstrual cycle. Future trial design needs to include such outcomes as participant satisfaction, cost‐effectiveness data, quality‐of‐life measures, and a longer duration of treatment (at least six months) to assess adverse events. Trials powered to detect any increased risk in VTE would be very helpful, but may require a prohibitively large number of patients to be enrolled. More information is needed on the efficacy of antifibrinolytic treatment in the treatment of self‐reported HMB. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000249-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000249-sec-0022"></div> <div class="table" id="CD000249-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antifibrinolytics compared to no treatment or placebo for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to no treatment or placebo for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with heavy menstrual bleeding<br/> <b>Setting</b> : gynaecology outpatient departments; one study simply said ''clinical sites''<br/> <b>Intervention</b> : antifibrinolytics<br/> <b>Comparison</b>: no treatment or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss<br/> Assessed with: alkaline haematin method<br/> Follow‐up: range 3 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss: mean loss ranged from 206 mL to 252 mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 53.2 mL lower<br/> (62.7 lower to 43.7 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>565<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates<br/> Assessed with a variety of methods<br/> Follow‐up: range 3 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000<br/> (200 to 662) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.34<br/> (1.84 to 6.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>836 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>990 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05 (0.93 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most of these adverse events were mild to moderate in severity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Only one thromboembolic event occurred in the two studies that reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level due to risk of bias (2 of 4 studies with unclear randomization and 1 with unclear allocation concealment and 1 study with high risk of attrition bias) </p> <p><sup>2</sup> Quality downgraded 1 level due to risk of bias (1 very small study with substantial risk of attrition bias) </p> <p><sup>3</sup> Quality downgraded 2 levels due to risk of bias (study had unclear allocation concealment and randomization method) and because of imprecision (single study). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000249-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antifibrinolytics compared to progestogens for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to progestogens for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with heavy menstrual bleeding<br/> <b>Setting</b> : any<br/> <b>Intervention</b> : antifibrinolytics<br/> <b>Comparison</b>: progestogens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss (overall)<br/> Assessed with: PBAC<sup>11</sup><br/> Follow‐up: range 2 months to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score ranged from 114 to 209 pts</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 12.22 pts lower<br/> (30.8 lower to 6.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two additional trials (at low risk of bias) had skewed data and are displayed in Additional Table 1. They both found a significant benefit for TXA. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates (overall)<br/> Assessed with: patient assessment<br/> Follow‐up: range 2 months to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>463 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>701 per 1000 (607 to 833)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.54<br/> (1.31 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>422<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall effect combining short‐ and long‐course progestogens.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> <p>Need to add CI here</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.46 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No thromboembolic events were diagnosed in either group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level due to inconsistency between the five trials, possibly linked to different measurement tools </p> <p><sup>2</sup> Quality downgraded further 2 levels due to risk of bias (3 of 5 studies with unclear allocation concealment, 2 of 5 studies had high risk of detection bias and 1 study had a high risk of attrition bias) </p> <p><sup>3</sup> Quality downgraded 2 levels due to risk of bias(high risk of detection and reporting bias) </p> <p><sup>4</sup> Quality downgraded a further level due to imprecision (the study was a single small trial) </p> <p><sup>5</sup> Quality downgraded 2 levels due to risk of bias (both trials at high risk of performance bias and 1 trial at high risk of attrition bias) </p> <p><sup>6</sup> Quality downgraded 2 levels due to risk of bias (3 of 4 studies with high risk of detection bias, 1 study with risk of attrition bias and 1 study with risk of reporting bias) </p> <p><sup>7</sup> Quality downgraded 2 levels due to risk of bias (2 of 3 studies with high risk of detection bias, 1 study at risk of reporting bias) </p> <p><sup>8</sup> Quality downgraded 2 levels due to risk of bias (one study with high risk of performance bias and attrition bias) </p> <p><sup>9</sup> Quality downgraded a further level because of imprecision (single small trial) </p> <p><sup>10</sup> Quality downgraded 2 levels due to risk of bias (2 of 3 studies with unclear allocation concealment, 1 study with unclear attrition bias, 1 study with high risk of selective outcome reporting and 2 studies with unclear 'other' bias) </p> <p><sup>11</sup> Some authors consider 100 points in the Pictorial Blood Assessment Chart (PBAC) equivalent to 80 mL of menstrual blood loss (i.e. heavy menstrual bleeding); some 150 points. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000249-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antifibrinolytics compared to NSAIDs for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to NSAIDs for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> all<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss<br/> Assessed with: alkaline haematin method<br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss: mean loss was 148 mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 73 mL lower<br/> (123.35 lower to 22.65 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates<br/> Assessed with: patient questionnaire<br/> Follow‐up: range 2 months to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>869 per 1000<br/> (717 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.43<br/> (1.18 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>The total number of adverse events per group were not measured. Individual adverse events were uncommon. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>These were not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level for study limitations (I study with unclear risk of selection bias) </p> <p><sup>2</sup> Quality downgraded a further level because of imprecision (single very small study) </p> <p><sup>3</sup> Quality downgraded 2 levels because of study limitations (both studies at high risk of performance bias as women assessed this outcome and knowledge of treatment may have influenced the findings) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000249-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antifibrinolytics compared to ethamsylate for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to ethamsylate for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> all<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> ethamsylate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ethamsylate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss<br/> Assessed with: alkaline haematin method<br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss: mean loss was 175 mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 100 mL lower<br/> (141.82 lower to 58.18 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates<br/> Assessed with: patient assessment<br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1000<br/> (422 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.56<br/> (0.95 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal from treatment because of adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78 (0.19 to 3.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Thromboembolic events were not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level due to risk of bias (single study with unclear allocation concealment) </p> <p><sup>2</sup> Quality downgraded 1 level due to risk of bias (single small study) </p> <p><sup>3</sup> Quality downgraded 2 levels due to risk of bias (single study with unclear allocation concealment and high risk of performance bias) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000249-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Antifibrinolytics compared to herbal medicines for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to herbal medicines for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> heavy menstrual bleeding<br/> <b>Setting:</b> all<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> herbal medicines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with herbal medicines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss ‐ after 3 months Rx<br/> Assessed with: PBAC<sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score ranged from 51 to 143 pts</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 23.90 pts lower (31.2 lower to 15.88 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One trial assessed a 'unani' formulation vs TXA and the other a pomegranate extract vs TXA </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss ‐ after 3 months' follow‐up from end of Rx<br/> Assessed with: PBAC<sup>4</sup><br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score was 71.3 pts</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10.4 pts lower<br/> (19.2 lower to 1.6 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC scores evaluated 3 months after Rx was completed in both groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.25 (0.74 to 6.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>The study did not measure any thromboembolic events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 2 levels due to risk of bias (one trial had unclear selection, performance, and attrition bias; the other had unclear attrition and other bias) </p> <p><sup>2</sup> Quality downgraded 1 level due to risk of bias(trial had unclear selection, performance and attrition bias) </p> <p><sup>3</sup> Quality downgraded 1 level because of imprecision (single small study) </p> <p><sup>4</sup>Some authors consider 100 points in the Pictorial Blood Assessment Chart (PBAC) equivalent to 80 mL of menstrual blood loss (i.e. heavy menstrual bleeding); some 150 points. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000249-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Antifibrinolytics compared to levonorgestrel intrauterine system</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with levonorgestrel for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> heavy menstrual bleeding </p> <p><b>Settings:</b> all </p> <p><b>Intervention:</b> antifibrinolytics </p> <p><b>Comparison:</b> levonorgestrel intrauterine system (IUS) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel IUS</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with TXA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: median difference in PBAC score ‐ after 6 months Rx</p> <p>Assessed with: PBAC<sup>4</sup> </p> <p>Follow‐up: outcomes measured at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>−252.0 (IQR 124.5) <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>−126.5 (IQR 104.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement in mean blood loss (PBAC score &lt; 100)</p> <p>Assessed with: PBAC<sup>4</sup> </p> <p>Follow‐up: outcomes measured at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>850 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000 (204 to 655)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.43 (0.24 to 0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83 (0.25 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>The study did not measure any thromboembolic events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IQR:</b> Interquartile Range; <b>OR:</b> Odds Ratio; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unable to calculate 'X per 1000 women', as the data are not in a normal distribution, but are skewed. </p> <p><sup>2</sup> Quality downgraded 2 levels due to the one trial being at high risk of: performance and detection bias; and attrition bias. </p> <p><sup>3</sup> Quality downgraded a further level because of imprecision (single small trial). </p> <p><sup>4</sup>Some authors consider 100 points in the Pictorial Blood Assessment Chart (PBAC) equivalent to 80 mL of menstrual blood loss (i.e. heavy menstrual bleeding); some 150 points. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000249-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000249-sec-0023"></div> <section id="CD000249-sec-0024"> <h3 class="title" id="CD000249-sec-0024">Description of the condition</h3> <p>‘Normal’ menstrual blood loss (MBL) has been defined as 30 mL to 40 mL per menstrual cycle, whilst heavy menstrual bleeding has traditionally been defined as greater than 80 mL blood loss per cycle (<a href="./references#CD000249-bbs2-0034" title="DuckittK , CollinsS . Menorrhagia. BMJ Clinical Evidence2012;01:805. ">Duckitt 2012</a>). Whilst this objective cut‐off has been broadly utilized in clinical trials, such measurement (involving extracting haemoglobin from sanitary wear) is impractical outside research settings. Also, this objectively measured cut‐off of 'heavy' menstrual bleeding may not reflect the woman's experience, nor the impact of heavy menstrual bleeding (HMB) on her quality of life (QoL) (<a href="./references#CD000249-bbs2-0056" title="WarnerPE , CritchleyHOD , LumsdenMA , Campbell‐BrownM , DouglasA , MurrayGD . Menorrhagia II: Is the 80mL blood loss criterion useful in management of complaint of menorrhagia?. American Journal of Obstetrics and Gynecology2004;190(5):1224‐9. ">Warner 2004</a>). International guidelines (such as that produced by the United Kingdom's National Institute for Health and Care Excellence (NICE)) base the diagnosis of HMB on women’s and clinicians’ subjective perceptions of MBL, and its resultant impact (e.g. iron‐deficiency anaemia, days off work). </p> <p>HMB is an important cause of ill health in women: prevalence estimates range from 4% to 51%. This wide range is due to these studies being undertaken in different countries and clinical settings (<a href="./references#CD000249-bbs2-0051" title="Royal College of Obstetricians and Gynaecologists. Heavy menstrual bleeding. National Institute for Health and Clinical Excellence; 2007 January. ">NICE 2007</a>). It has been estimated that HMB accounts for 5% of general practitioner consultations by women aged 30 to 49 years old (<a href="./references#CD000249-bbs2-0055" title="TurnerE , BowieP , KellockC . First‐line management of menorrhagia: findings from a survey of general practitioners in Forth Valley. British Journal of Family Planning2000;26(4):227‐8. ">Turner 2000</a>), whilst HMB accounts for up to one‐third of all gynaecological consultations (<a href="./references#CD000249-bbs2-0036" title="El‐HemaidiI , GharaibehA , ShehataH . Menorrhagia and bleeding disorders. Current Opinion in Obstetrics &amp; Gynecology2007;19(6):513‐20. ">El‐Hemaidi 2007</a>). </p> <p>The most widely used classification system for causes of abnormal uterine bleeding in reproductive‐aged women is that of the International Federation of Gynecology and Obstetrics, called the PALM‐COEIN system. As outlined in <a href="./references#CD000249-bbs2-0049" title="MunroMG , CritchleyHO , BroderMS , FraserIS . FIGO classification system (PALM‐COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology and Obstetrics2011;113(1):3‐13. ">Munro 2011</a>, the basic classification system breaks aetiologies down into: Polyp; Adenomyosis; Leiomyoma (submucosal/other); Malignancy and hyperplasia; Coagulopathy; Ovulatory dysfunction; Endometrial; Iatrogenic; and Not yet classified. In general, the PALM aetiologies are structural, whilst the COEIN categories are non‐structural. </p> <p>Around 80% of women treated for heavy menstrual bleeding have no underlying uterine abnormality (i.e. would fall into the COEIN categories listed above), yet up to 60% of women referred to a gynaecologist for HMB undergo a hysterectomy within five years of referral (<a href="./references#CD000249-bbs2-0035" title="EdlandM , BlombackM , HeS . On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagulation &amp; Fibrinolysis2003;14(6):593‐8. ">Edlund 2003</a>; <a href="./references#CD000249-bbs2-0053" title="QiuJ , ChengJ , WangQ , HuaJ . Levonogestrel‐releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta‐analysis. Medical Science Monitor2014;20:1700‐13. ">Qiu 2014</a>). HMB is the primary indication for approximately 50% of all hysterectomies (emergency plus elective) in the UK (<a href="./references#CD000249-bbs2-0055" title="TurnerE , BowieP , KellockC . First‐line management of menorrhagia: findings from a survey of general practitioners in Forth Valley. British Journal of Family Planning2000;26(4):227‐8. ">Turner 2000</a>), and 38% of all elective hysterectomies (<a href="./references#CD000249-bbs2-0033" title="ButtJL , JefferyST , Van derSpuyZM . An audit of indications and complications associated with elective hysterectomy at a public service hospital in South Africa. International Journal of Gynaecology and Obstetrics2012;116(2):112‐6. ">Butt 2012</a>). </p> <p>Hence medical therapy, with the avoidance of potential complications of surgical management, is an attractive alternative. A wide variety of medications are available to reduce heavy menstrual bleeding, but there is considerable variation in practice, and some uncertainty about the most appropriate first line therapy: a universally applicable step‐wise approach is sorely lacking (<a href="./references#CD000249-bbs2-0038" title="FoxK . Management of heavy menstrual bleeding in general practice. Current Medical Research and Opinion2012;28(9):1517‐25. ">Fox 2012</a>; <a href="./references#CD000249-bbs2-0047" title="MarretH , FauconnierA , Chabbert‐BuffetN , CravelloL , GolfierF , GondryJ , et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2010;152(2):133‐7. ">Marret 2010</a>). </p> </section> <section id="CD000249-sec-0025"> <h3 class="title" id="CD000249-sec-0025">Description of the intervention</h3> <p>Trans‐4‐aminomethylcyclohexanocarboxylic acid (or tranexamic acid and its precursors) is an antifibrinolytic medication. Tranexamic acid (TXA) has been used to treat HMB for over four decades in many European countries; in the UK, TXA is prescribed as first‐ or second‐line medical management of HMB for over 64% of women not requiring contraception (<a href="./references#CD000249-bbs2-0055" title="TurnerE , BowieP , KellockC . First‐line management of menorrhagia: findings from a survey of general practitioners in Forth Valley. British Journal of Family Planning2000;26(4):227‐8. ">Turner 2000</a>). In the US, TXA was not approved for the treatment of menorrhagia until 2009 (<a href="./references#CD000249-bbs2-0044" title="KaunitzA . A new treatment for menorrhagia enters the US market. OBG Management2010;22(6):34‐5. ">Kaunitz 2010</a>). </p> </section> <section id="CD000249-sec-0026"> <h3 class="title" id="CD000249-sec-0026">How the intervention might work</h3> <p>Women with HMB have been found to have increased fibrinolytic activity in their menstrual fluid (<a href="./references#CD000249-bbs2-0035" title="EdlandM , BlombackM , HeS . On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagulation &amp; Fibrinolysis2003;14(6):593‐8. ">Edlund 2003</a>). </p> <p>TXA exerts its antifibrinolytic effect by reversibly blocking lysine‐binding sites on plasminogen, thus preventing plasmin from interacting with lysine residues on the fibrin polymer. By preventing plasmin and lysine residues from interacting, TXA thus slows subsequent fibrin degradation, thereby slowing the dissolution of clots. Antifibrinolytic agents have, therefore, been promoted as a treatment for heavy menstrual bleeding. </p> </section> <section id="CD000249-sec-0027"> <h3 class="title" id="CD000249-sec-0027">Why it is important to do this review</h3> <p>There is growing evidence of the utility of the levonorgestrel intrauterine system (LIUS) in managing heavy menstrual bleeding. Qiu et al published a systematic analysis comparing the levonorgestrel intrauterine device to medical management of HMB, and included <a href="./references#CD000249-bbs2-0040" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonogestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368(2):128‐37. ">Gupta 2013</a>, a randomized controlled trial (RCT) which compared LIUS to medical management of HMB (<a href="./references#CD000249-bbs2-0040" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonogestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368(2):128‐37. ">Gupta 2013</a>; <a href="./references#CD000249-bbs2-0053" title="QiuJ , ChengJ , WangQ , HuaJ . Levonogestrel‐releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta‐analysis. Medical Science Monitor2014;20:1700‐13. ">Qiu 2014</a>). The authors concluded that LIUS is more effective for the treatment of HMB compared with oral medical treatment. However, for women for whom an intrauterine device is contra‐indicated or who wish to avoid an LIUS, antifibrinolytic treatment still plays an important role. </p> <p>Although TXA has been credited with reducing MBL by up to 60% (<a href="./references#CD000249-bbs2-0045" title="LeminenH , HurskainenR . Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. International Journal of Women's Health2012;4:413‐21. ">Leminen 2012</a>), one study based in Somerset (UK) found that less than 15% of women presenting to their general practitioner complaining of HMB were offered antifibrinolytic treatment (<a href="./references#CD000249-bbs2-0039" title="GrantC , GallierL , FaheyT , PearsonN , SarangiJ . Management of menorrhagia in primary care ‐ impact on referral and hysterectomy: data from the Somerset Morbidity Project. Journal of Epidemiology and Community Health2000;54(9):709‐13. ">Grant 2000</a>). Recent data indicate that prescribing patterns may be changing: a randomized controlled trial carried out in general practices in East Anglia (in the UK) indicated rates of antifibrinolytic use among women with heavy menstrual bleeding were 57% among those practices given a specific evidence‐based education package, and 35% among control practices (<a href="./references#CD000249-bbs2-0037" title="FenderGRK , PrenticeA , GorstT , NixonRM , DuffySW , DayNE , et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ1999;318(7193):1246‐50. ">Fender 1999</a>). </p> <p>As these medications slow the breakdown of clots, there has been anecdotal concern that antifibrinolytic agents may be associated with an increased risk of thromboembolic disease (such as deep venous thrombosis). However, venous thromboembolic events have not been reported in treatment studies, and (to date) data from population‐based studies do not support an increased incidence of venous thromboembolism with antifibrinolytic use (<a href="./references#CD000249-bbs2-0045" title="LeminenH , HurskainenR . Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. International Journal of Women's Health2012;4:413‐21. ">Leminen 2012</a>). Long‐term studies in Sweden have shown that the incidence of thrombosis in women treated with TXA is comparable to that of women not being treated with TXA (<a href="./references#CD000249-bbs2-0032" title="BerntorpE , FollrudC , LethagenS . No increased risk of venous thrombosis in women taking tranexamic acid. Thrombosis and Haemostasis2001;86(2):714‐5. ">Berntorp 2001</a>). </p> <p>Hence, it is important to do this review to assess antifibrinolytic treatment's efficacy in managing heavy menstrual bleeding, which will be particularly relevant for women who are unable/unwilling to have a LIUS inserted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000249-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000249-sec-0028"></div> <p>To determine the effectiveness and safety of antifibrinolytics as a treatment for heavy menstrual bleeding </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000249-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000249-sec-0029"></div> <section id="CD000249-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000249-sec-0031"> <h4 class="title">Types of studies</h4> <p>We accepted as eligible for inclusion published and unpublished RCTs of antifibrinolytic therapy versus placebo, no treatment or any other medical (non‐surgical) therapy when used to reduce heavy menstrual bleeding. We excluded non‐randomized studies (e.g. studies with evidence of inadequate sequence generation such as alternate days, patient numbers) as they are associated with a high risk of bias. </p> <p>Cross‐over trials were only eligible for inclusion if they reported first‐phase data, in order to minimise the chance of cross‐over bias. This is a change from the original protocol criteria for inclusion, where cross‐over trials could be included regardless of whether data were provided for the first phase of the trial. Where cross‐over trials only report findings at the end of the study the likelihood of significant bias is increased, because no adjustment is made for cross‐over effects. </p> </section> <section id="CD000249-sec-0032"> <h4 class="title">Types of participants</h4> <p>Women of reproductive age, who are having regular heavy periods (measured either objectively or subjectively), undertake at least two months' follow‐up whilst on treatment, and who are recruited from primary care, family planning, or a specialist clinic setting were eligible for inclusion. </p> <p>Exclusion criteria included: post‐menopausal bleeding; irregular menses, inter‐menstrual bleeding or both; pathological causes of HMB (e.g. a coagulopathy); and iatrogenic causes of HMB (e.g. intrauterine device/system, or anti‐coagulant medication). </p> </section> <section id="CD000249-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing antifibrinolytic agents (e.g. tranexamic acid and its precursors) versus no treatment, placebo, or any other medical (non‐surgical) therapy. We excluded studies that used combined treatments (e.g. a LIUS with concurrent oral TXA). </p> </section> <section id="CD000249-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD000249-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>1. Menstrual blood loss (MBL), measured by either or both of the following.</p> <p>a) Objective assessment of mean blood loss in mL (using alkaline haematin method or similar, <a href="./references#CD000249-bbs2-0041" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation1964;16:244‐8. ">Hallberg 1964</a>), using either change scores or end scores: where studies reported both, we used end scores. </p> <p>b) Subjective assessment of blood loss using continuous measures such as Pictorial Blood Assessment Chart (PBAC) scores, using either change scores or end scores: where studies reported both, we used end scores. PBAC scores range from 0 to more than 500, and rely on women scoring each tampon and sanitary towel they use during the course of a period, in terms of how heavily blood‐stained they are. Blood clots and episodes of flooding are also recorded (<a href="./references#CD000249-bbs2-0043" title="HighamJ , O'BrienP , ShawR . Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology1990;97:734‐9. ">Higham 1990</a>). Studies have confirmed a significant correlation between PBAC score and the alkaline haematin method, with a PBAC score of more than 100 being indicative of HMB (<a href="./references#CD000249-bbs2-0057" title="ZakherahM , SayedG , El‐NasharA , ShaabanM . Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecologic and Obstetric Investigation2011;71(4):281‐4. ">Zakherah 2011</a>). </p> <p>2. Improvement in HMB: binary measures (improved/not improved) as reported by the study, giving priority to subjective measures if studies reported both. </p> <p>3. Thromboembolic events.</p> </section> <section id="CD000249-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>4. Quality of life: participant's perceived change in quality of life from baseline provided this has been recorded in a reproducible and validated format (e.g. Menorrhagia Impact Questionnaire (MIQ), SF‐36, WHOQOL‐BREF). </p> <p>5. Adverse events (other than thromboembolic events), including but not limited to: any adverse event; gastrointestinal side effects; abdominal discomfort; headaches; dizziness; breast tenderness; dysmenorrhoea; changes in weight; and changes in mood. </p> </section> </section> </section> <section id="CD000249-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished randomized controlled trials of antifibrinolytic therapy for the treatment of heavy menstrual bleeding, without language restriction and in consultation with the Gynaecology and Fertility Group (CGF) Information Specialist. </p> <section id="CD000249-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases for relevant trials.</p> <p>1. The Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of Controlled Trials (PROCITE platform) (searched 7 November 2017) (<a href="./appendices#CD000249-sec-0139">Appendix 1</a>). </p> <p>2. The Cochrane Central Register of Controlled Trials in the Cochrane Library, via the Cochrane Register of Studies Online (CRSO Web platform) (searched 7 November 2017) (<a href="./appendices#CD000249-sec-0140">Appendix 2</a>). </p> <p>3. MEDLINE (OVID platform) (searched from 1946 to 7 November 2017) (<a href="./appendices#CD000249-sec-0141">Appendix 3</a>). </p> <p>4. Embase (OVID platform) (searched from 1980 to 7 November 2017) (<a href="./appendices#CD000249-sec-0142">Appendix 4</a>). </p> <p>5. PsycINFO (OVID platform) (searched from 1806 to 7 November 2017)  (<a href="./appendices#CD000249-sec-0143">Appendix 5</a>). </p> <p>The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials which appears in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (Version 5.1.0 chapter 6, 6.4.11). The Embase, PsycINFO and CINAHL searches are combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="http://www.sign.ac.uk/assets/search-filters-randomised-controlled-trials.docx" target="_blank">www.sign.ac.uk/assets/search‐filters‐randomised‐controlled‐trials.docx</a>). </p> <p>Other electronic sources of trials included:</p> <p>6. trial registers for ongoing and registered trials –</p> <p> <ul id="CD000249-list-0001"> <li> <p><a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> (a service of the US National Institutes of Health) </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a> (The World Health Organization International Trials Registry Platform search portal) </p> </li> </ul> </p> <p>7. LILACS (Latin American and Caribbean Health Science Information database (from 1982 ongoing) and other Spanish and Portuguese language databases, found in the Virtual Health Library Regional Portal (VHL): <a href="http://lilacs.bvsalud.org" target="_blank">lilacs.bvsalud.org</a><br/> 8. PubMed and Google Scholar (for recent trials not yet indexed in the major databases) </p> <p>These databases were searched using the following subject headings and keywords: menorrhagia, dysfunctional uterine bleeding, heavy menstrual bleeding, antifibrinolytic, tranexamic acid, trans‐4‐aminomethylcyclohexanocarboxylic acid, KABI. Please see the Appendices for details. </p> </section> <section id="CD000249-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of relevant trials and systematic reviews retrieved by the search and contact experts in the field to obtain additional data. We also handsearched relevant journals and conference abstracts that are not covered in the CGF register, in liaison with the Information Specialist. Marian Showell (Information Specialist for the Cochrane Gynaecology and Fertility Group (CGF)) performed the initial search, whilst AB‐S searched other electronic sources and resources. </p> </section> </section> <section id="CD000249-sec-0040"> <h3 class="title" id="CD000249-sec-0040">Data collection and analysis</h3> <section id="CD000249-sec-0041"> <h4 class="title">Selection of studies</h4> <p>The initial search was conducted by Marian Showell. After an initial screen of titles and abstracts retrieved by the search, conducted by AB‐S and AL, we retrieved the full texts of all potentially eligible studies. Two review authors (AB‐S and AL) independently examined these full text articles for compliance with the inclusion criteria and selected eligible studies. We corresponded with study investigators as required, to clarify study eligibility. Disagreements were resolved by discussion. If any reports required translation, we described the process used for data collection. We documented the selection process with a PRISMA flow chart (<a href="#CD000249-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD000249-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (PRISMA chart)." data-id="CD000249-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (PRISMA chart).</p> </div> </div> </div> </section> <section id="CD000249-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AB‐S and AL) independently extracted data from eligible studies using a data extraction form designed and pilot‐tested by the authors. We resolved any disagreements by discussion; or if deadlock persisted, by involving a third review author as arbitrator. Data extracted included study characteristics and outcome data (see <a href="#CD000249-sec-0040">Data collection and analysis</a> section for details). Where studies had multiple publications, we used the main trial report as the reference and derived additional details from secondary papers. </p> <p>We corresponded with study investigators for further data on methods or results (or both), as required. </p> </section> <section id="CD000249-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AB‐S and AL) independently assessed the included studies for risk of bias using the Cochrane 'Risk of bias' assessment tool to assess: selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other bias (<a href="./references#CD000249-bbs2-0042" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org. ">Higgins 2011</a>). We assigned judgement as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Section 8.5 (<a href="./references#CD000249-bbs2-0042" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved disagreements by discussion; or if deadlock persisted, by involving a third review author as arbitrator. We described all judgements fully and present the conclusions in the 'Risk of bias' table, which we incorporated into the interpretation of review findings by means of sensitivity analyses (see below). </p> <p>With respect to within‐trial selective reporting, where identified studies fail to report the primary outcome of live birth, but do report interim outcomes such as pregnancy, we assessed whether the interim values are similar to those reported in studies that also report live birth. </p> </section> <section id="CD000249-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (e.g. adverse event rates), we used the numbers of events in the control and intervention groups of each study to calculate Mantel‐Haenszel risk ratios (RRs). For continuous data (e.g. MBL in mL), if all studies report exactly the same outcomes we calculated mean difference (MDs) between treatment groups. If similar outcomes are reported on different scales we calculated the standardized mean difference (SMD). We reversed the direction of effect of individual studies, if required, to ensure consistency across trials. We treated ordinal data (e.g. quality of life scores) as continuous data. We presented 95% confidence intervals for all outcomes. Where data to calculate ORs or MDs are not available, we utilized the most detailed numerical data available that facilitated similar analyses of included studies (e.g. test statistics, P values). We assessed whether the estimates calculated in the review for individual studies are compatible in each case with the estimates reported in the study publications. </p> <p>We included either end score or change score data for measuring MBL. Where studies report both, we used end scores. For the primary outcome, we considered whether the data underlying the published result were likely to be skewed by examining the ratio of each group mean to its standard deviation. Where end scores were reported, a ratio considerably less than two indicates positive skewness, due to the fact that 'menstrual bleeding' cannot take values less than zero. Where this was deemed to be the case, we reported the results in an additional table, as they could not be pooled in the meta‐analysis without access to the raw underlying data. Where no standard deviations were reported, we took a corresponding value reported in another similar study. </p> <p>Where studies reported standard deviations that were implausibly small, we assumed that these were in fact standard errors, and converted them to standard deviations, using standard methods (<a href="./references#CD000249-bbs2-0042" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD000249-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per woman randomized. Only first‐phase data from cross‐over trials was included. </p> </section> <section id="CD000249-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We analyzed the data on an intention‐to‐treat basis as far as possible (i.e. including all randomized participants in analysis, in the groups to which they were randomized). Attempts were made to obtain missing data from the original trialists. Where these are unobtainable, we undertook imputation of individual values for primary outcomes only. For other outcomes, we analyzed only the available data. Any imputation undertaken was subjected to sensitivity analysis (see below). </p> <p>If studies reported sufficient detail to calculate mean differences but no information on associated standard deviation (SD), we assumed the outcome to have a standard deviation equal to the highest SD from other studies within the same analysis. </p> </section> <section id="CD000249-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by the measure of the I² statistic. An I² measurement greater than 50% was taken to indicate substantial heterogeneity (<a href="./references#CD000249-bbs2-0042" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD000249-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, the authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies, and by being alert for duplication of data. If there were 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD000249-sec-0049"> <h4 class="title">Data synthesis</h4> <p>If the studies were sufficiently similar, we combined the data using a fixed‐effect model in the following comparisons. </p> <p> <ol id="CD000249-list-0002"> <li> <p>Antifibrinolytics versus placebo or no treatment.</p> </li> <li> <p>Antifibrinolytics versus any other medical (non‐surgical) treatment.</p> </li> </ol> </p> <p>Any increase in the odds of a particular outcome, either beneficial (e.g. decreased MBL) or detrimental (e.g. adverse effects), were displayed graphically in the meta‐analyses to the right of the centre line, and a decrease in the odds of an outcome to the left of the centre line. </p> </section> <section id="CD000249-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data are available, we conducted subgroup analyses to determine the separate evidence within the following subgroups. </p> <p> <ol id="CD000249-list-0003"> <li> <p>Tranexamic acid dose (&lt; 3 g/day versus ≥ 3 g/day)</p> </li> <li> <p>Different methods of measuring MBL: objectively, by the alkaline haematin method and subjectively by the PBAC </p> </li> <li> <p>Differences between the control interventions (e.g. luteal phase norethisterone (NET) or medroxyprogesterone (MPA)) </p> </li> </ol> </p> <p>If we detected substantial heterogeneity, we explored possible explanations in sensitivity analyses. We took any statistical heterogeneity into account when interpreting the results, especially if there was any variation in the direction of effect. </p> </section> <section id="CD000249-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses for the primary outcomes to determine whether the conclusions are robust to arbitrary decisions made regarding the eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if: </p> <p> <ol id="CD000249-list-0004"> <li> <p>eligibility were restricted to studies without high risk of bias;</p> </li> <li> <p>a random‐effects model had been adopted;</p> </li> <li> <p>alternative imputation strategies had been implemented;</p> </li> <li> <p>the summary effect measure was relative risk rather than odds ratio.</p> </li> </ol> </p> <section id="CD000249-sec-0052"> <h5 class="title"><i>Overall quality of the body of evidence: 'Summary of findings' table</i> </h5> <p>We prepared a 'Summary of findings' table using GRADEpro and Cochrane methods. This table evaluates the overall quality of the body of evidence for the main review outcomes (MBL, adverse events) for the main review comparison (antifibrinolytic agent versus placebo or other medical therapy). Additional 'Summary of findings' tables were also prepared for the main review outcomes for other important comparisons (antifibrinolytic agent versus progestogens, antifibrinolytic agent versus ethamsylate etc.). We assessed the quality of the evidence using GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness and publication bias). Two review authors working independently made judgements about evidence quality (high, moderate, low or very low), with disagreements resolved by discussion. Judgements were justified, documented, and incorporated into reporting of results for each outcome. </p> <p>We extracted study data, formatted our comparisons in data tables, and prepared a 'Summary of findings' table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000249-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000249-sec-0053"></div> <section id="CD000249-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD000249-sec-0055"> <h4 class="title">Results of the search</h4> <p>The 2010 version of this review included seven studies. Our new search retrieved 191 articles. Eighteen studies not included in the previous version of this review were potentially eligible and were retrieved in full text. Nine of these new studies met our inclusion criteria. We excluded three studies from the 2010 version of this review, and there are no studies awaiting classification; (see study tables: <a href="./references#CD000249-sec-0159" title="">Characteristics of included studies</a>, <a href="./references#CD000249-sec-0160" title="">Characteristics of excluded studies</a>). </p> <p>See <a href="#CD000249-fig-0001">Figure 1</a> for the relevant PRISMA flow chart. </p> </section> <section id="CD000249-sec-0056"> <h4 class="title">Included studies</h4> <section id="CD000249-sec-0057"> <h5 class="title">Study design and setting</h5> <p>Thirteen studies are included in the current update of the review, twelve with a parallel group design and one cross‐over trial. </p> <p>Seven of the studies were single‐centre; the country settings included Ireland, UK, India, Turkey, and Iran. The remaining studies drew subjects from various sites across individual countries (Sweden, USA, Thailand, Iran and China). </p> </section> <section id="CD000249-sec-0058"> <h5 class="title">Participants</h5> <p>The studies (1312 participants) included 582 women in the control (non‐antifibrinolytic) groups and 778 in the intervention (i.e. tranexamic acid) groups. Their age ranged across studies from 15 to 50 years. Of note: <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a> included women less than 18 years old without confirming that their HMB was ovulatory, whilst <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a> and <a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a> only included women more than 32 years old. </p> <p><a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> was the only study to use BMI as an inclusion criterion (19 to 29 kg/m<sup>2</sup>). </p> <p>Several studies used serum haemoglobin as an inclusion criterion: <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>, <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a> and <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> required women to have a serum haemoglobin of more than 8 g/dL; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> used a cut‐off of more than 10 g/dL; whilst <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> and <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a> required women to have a serum haemoglobin of more than 10.5 g/dL </p> <p>Three studies excluded women with a self‐reported history of irregular menstrual bleeding (<a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>); whilst <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; and <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> tested mid‐luteal progesterone to confirm that HMB was ovulatory. </p> <p>All studies except <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> mentioned excluding women with an underlying pelvic aetiology of their HMB, although several did not elucidate how they excluded pelvic pathology (i.e. by history, examination, ultrasound, hysteroscopy or endometrial biopsy, or a combination of these). </p> <p><a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> included women with leiomyomata. <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> and <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a> excluded women found to have uterine leiomyomata, whilst <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a> and <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> only excluded women with fibroids thought to warrant surgical management. <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a> excluded women with fibroids greater than 3 cm in diameter, and <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> excluded women with fibroids that were greater than 2 cm or indented the uterine cavity on ultrasound. </p> <p>Several studies mentioned adenomyosis: <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> included women with adenomyosis, whilst <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a> specifically excluded women thought to have adenomyosis. </p> <p><a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>, <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>, <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>, <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> and <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> required a negative Pap smear within 0 to 12 months of trial entry. <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> excluded women with malignant cervicovaginal pathology. </p> <p>The following studies excluded women who were taking medications that might affect their menstrual pattern (such as anticoagulants, aspirin, or NSAIDs/COX‐2 inhibitors during the menstrual phase of their cycle): <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>. Several studies listed hormonal contraception as an exclusion criterion (<a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>). <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> excluded women with a history of having taken medications for menorrhagia previously. </p> <p>With regard to non‐gynaecological and non‐haematological co‐morbidities: <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>, <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>, <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> excluded women with renal/hepatic dysfunction, and <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> those with renal dysfunction. <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>, <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>, <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>, <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>, <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>, <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> mentioned excluding women with either a history of, or definitive proof of, a coagulopathy or fibrinolytic disorder. <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> measured participants' coagulation profile. </p> <p>The following studies excluded women who reported a history of venous thromboembolism: <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>. <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a> also excluded women with a history of arterial thrombosis (i.e. ischaemic heart disease, acute myocardial infarction, stroke/cerebrovascular accident, transient ischaemic attack); <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> excluded women with coronary artery disease. The following studies excluded women with a history of coagulopathy/fibrinolytic disorder: <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; and <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>. </p> <p><a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>, <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>, <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>, and <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a> excluded women with thyroid disease, whilst <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a> also excluded women with hyperprolactinaemia. </p> <p>There were several co‐morbidities that were used as an exclusion criterion by only one study: <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a> excluded women with inflammatory bowel disease, peptic/intestinal ulceration; <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> excluded women with a history of diabetes, hypertension, tuberculosis, "malignancies" or hypothalamic pituitary dysfunction; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> excluded women with hypertension or diabetes; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> excluded women with a history of sub‐arachnoid haemorrhage, "endocrinopathy" or ocular disease. </p> <p><a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> simply reports excluding women with any "history of chronic diseases". </p> </section> <section id="CD000249-sec-0059"> <h5 class="title">Interventions</h5> <p>The thirteen studies (twelve parallel group, and one cross‐over trial) used various antifibrinolytic formulations and dosage regimens, as detailed below. </p> <p>Tranexamic acid, used by 12 of the 13 studies, is a synthetic analogue of the amino acid lysine. Kabi (used in <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>) is a pro‐drug of TXA. </p> <section id="CD000249-sec-0060"> <h6 class="title">Dosage</h6> <p>The majority of studies used regular dose TXA (ranging from 3 g/day to 4 g/day) (<a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a>; <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>). </p> <p>Four other studies used low‐dose TXA (ranging from 2 g/day to 2.4 g/day) (<a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>). </p> <p><a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a> compared low‐dose (1.95 g/day) to regular‐dose TXA (3.9 g/day) to placebo. </p> </section> <section id="CD000249-sec-0061"> <h6 class="title">Treatments</h6> <p>Four studies compared antifibrinolytic treatment to placebo: <a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a> (a cross‐over trial); <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; and <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> (all parallel group studies). No studies compared antifibrinolytic treatment to no treatment. </p> <p>Nine studies compared antifibrinolytic treatment to other medical therapies: <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>; <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>. Of note: some studies compared antifibrinolytic treatment to two different alternative medical options. </p> <p> <ul id="CD000249-list-0005"> <li> <p>6 assessed progestogens (short or long course) (<a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>) </p> </li> <li> <p>2 assessed NSAIDs (<a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>) </p> </li> <li> <p>1 assessed ethamsylate (<a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>) </p> </li> <li> <p>2 assessed herbal remedies (one assessed Safoof Habis, and another pomegranate flower) (<a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>) </p> </li> <li> <p>1 assessed levonorgestrel intrauterine system (LIUS)</p> </li> </ul> </p> <p>Of the six studies that compared TXA to progestogens, four — <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>, <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>, <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> — compared TXA to short‐course progestogen (e.g. days 19 to 26 of the menstrual cycle only), whilst two — <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> and <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a> — compared TXA to long‐course progestogens (e.g. from days 5 to 26). </p> <p>One study compared antifibrinolytic treatment to a Unani formulation called Safoof Habis (<a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>). Unani is a type of traditional medicine widely practised in South‐East Asia. Safoof Habis is made up of: Teen Ahmer (silicate of alumina and iron oxide); Sange Jarahat (hydrated magnesium silicate); and Raal Sufaid (<i>Vateria indica</i> Linn, which is a species of plant in the <i>Disterocarpaceae</i> family, endemic to India). In <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> the treatment arm (Safoof Habis) was made up of equal parts of all three components, and given in 5 g doses twice per day, from days 1 to 5. </p> <p>One study compared TXA (500 mg four times per day on days 1 to 5) to <i>Punica granatum</i> Linn (pomegranate flower) (500 mg four times per day on days 1 to 5) (<a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>). </p> </section> </section> <section id="CD000249-sec-0062"> <h5 class="title">Outcomes</h5> <section id="CD000249-sec-0063"> <h6 class="title">Objective assessment of women's menstrual blood loss</h6> <p>Five parallel group studies confirmed the participants' HMB with objective testing such as alkaline haematin testing (<a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>). The alkaline haematin method of quantifying MBL was developed by Hallberg and Nilsson in the 1960s, and involves women collecting their menstrual pads, then sending them to the lab for analysis (for extraction and measurement of the amount of blood) (<a href="./references#CD000249-bbs2-0041" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation1964;16:244‐8. ">Hallberg 1964</a>). </p> <p>The one cross‐over study used the Oxford total body counter as a way of quantifying participants' MBL (<a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a>). </p> </section> <section id="CD000249-sec-0064"> <h6 class="title">Subjective assessment of women's menstrual blood loss</h6> <p>Seven studies — <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a>, <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>, <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>, <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>, <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>, <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a> and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> — assessed women’s menstrual bleeding by Pictorial Blood Assessment Chart (PBAC) (<a href="./references#CD000249-bbs2-0043" title="HighamJ , O'BrienP , ShawR . Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology1990;97:734‐9. ">Higham 1990</a>). </p> <p>The PBAC involves women recording the number of pads/tampons used, and documenting the degree of soiling. The PBAC has its limitations: for instance it is binary in nature and there is no international consensus on the cut‐off level for the definition of HMB. Some authors consider 100 points in the PBAC to be equivalent to 80 mL of MBL (i.e. HMB); some 150 points. Also, the PBAC does not allow for a volumetric correlation between the patient's PBAC score, and the volume of MBL. </p> </section> <section id="CD000249-sec-0065"> <h6 class="title">Self‐reported improvement in HMB</h6> <p>The gold standard for diagnosing HMB is patient's self‐reported assessments of their own menstrual loss. Six studies asked women to self‐report heavy menstrual bleeding, using a questionnaire (<a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a>; <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>). </p> </section> <section id="CD000249-sec-0066"> <h6 class="title">Quality of life measures</h6> <p>Eight studies reported quality of life measures. <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>, <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>, <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a> and <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> used the Menorrhagia Impact Questionnaire (with lower scores representing better quality of life). In addition, <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> and <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a> also used the SF‐36 quality of life questionnaire (with higher scores representing better quality of life). <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> used a questionnaire which included six questions relating to the impact of HMB on impairment of social life, work performance, tiredness, productivity, appetite and depression; (these data could not be used because measures of variation were not reported). <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> used the World Health Organization's Quality of Life‐Short Form, Turkish version (WHOQOL‐BREF TR), in which patients report limitations in physical health, psychological status, social support, and limitations relating to their environment. <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> used a 5‐point scale for quality‐of‐life assessments, which evaluated general health, flooding and leakage, abdominal pain, limitation on social activities, and effect on sex life. <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> used a 6‐item questionnaire, but it was not clear whether it was validated, or what specific items were assessed. </p> </section> <section id="CD000249-sec-0067"> <h6 class="title">Adverse events</h6> <p>Eleven studies reported adverse events (other than thromboembolic events): <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a>; <a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a>; <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>. The adverse events reported included: abdominal pain, allergic reaction, anxiety, back pain, bloating, breast tenderness, depression, chest pain, diarrhoea, dizziness, dysmenorrhoea, dyspepsia, excess hair growth, headache, intermenstrual bleeding, menstrual cramps, mood changes, myalgia, nausea, ocular events (lenticular opacities, blurred vision), rash, vaginal dryness, vertigo, vomiting, weight gain. </p> </section> </section> </section> <section id="CD000249-sec-0068"> <h4 class="title">Excluded studies</h4> <p>Nine studies were excluded from this version of the review, for the following reasons.</p> <p> <ul id="CD000249-list-0006"> <li> <p>1/9 was not a RCT (<a href="./references#CD000249-bbs2-0021" title="MuseK , GerstenJ , WaldbaumA , MabeyRG , LukesA , MooreK . Long‐term quality of life and safety of a new tranexamic acid menorrhagia treatment. Fertility and Sterility2010;94(4):S13. ">Muse 2010)</a> </p> </li> <li> <p>1/9 only included women who had a proven coagulopathy (<a href="./references#CD000249-bbs2-0019" title="KouidesPA , ByamsVR , PhillipCS , SteinSF , HeitJA , LukesAS , et al. Multisite management study of menorrhagia with abnormal haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. British Journal of Haematology2009;145(2):212‐20. ">Kouides 2009</a>) </p> </li> <li> <p>1/9 compared women taking tranexamic acid to women taking a combination of tranexamic and mefenamic acids (<a href="./references#CD000249-bbs2-0022" title="NajamR , AgarwalD , TyagiR , SinghS . Comparison of tranexamic acid with a combination of tranexamic acid and mefenamic acid in reducing menstrual blood loss in ovulatory dysfunctional uterine bleeding (DUB). Journal of Clinical and Diagnostic Research2010;4(5):3020‐5. ">Najam 2010</a>) </p> </li> <li> <p>4/9 were cross‐over trials that did not provide data at the end of the first phase of the study, before participants were crossed over (<a href="./references#CD000249-bbs2-0014" title="AnderschB , MilsomI , RyboG . An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstetricia et Gynecologica Scandinavica1988;67(7):645‐8. ">Andersch 1988</a>; <a href="./references#CD000249-bbs2-0026" title="NilssonL , RyboG . Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). Acta Obstetricia et Gynecologica Scandinavica1967;46:572‐80. ">Nilsson 1967</a>; <a href="./references#CD000249-bbs2-0024" title="NCT01428713 . Tranexamic acid (TA) vs combined oral contraceptive (COCP) pilot study. clinicaltrials.gov/ct2/show/NCT01428713 (first received 5 September 2011). ">NCT01428713</a>; <a href="./references#CD000249-bbs2-0029" title="VermylenJ , Verhaegen‐DeclercqML , VerstraeteM , FierensF . A double blind study of the effect of tranexamic acid in essential menorrhagia. Bulletin de la Societe Royale Belge de Gynecologie et d'Obstetrique1968;38:385‐90. VermylenJ , Verhaegen‐DeclercqML , VerstraeteM , FierensF . A double blind study of the effect of tranexamic acid in essential menorrhagia. Thrombosis et Diathesis Haemorrhagica1968;20:583‐7. ">Vermylen 1968</a>) </p> </li> <li> <p>2/9 were excluded when no response was received from the authors after several attempts to contact them (<a href="./references#CD000249-bbs2-0020" title="MoghtadaeiP . Different medication [sic] for heavy menstrual bleeding. 3rd International and 18th National Congress of Iranian Society for Reproductive Medicine; 2012. 2012:42. ">Moghtadaei 2012</a>; <a href="./references#CD000249-bbs2-0028" title="TabatabaeiA . A clinical randomized single blind trial of medical therapies for menorrhagia using ibuprofen and tranexamic acid. International Journal of Fertility and Sterility2013;7:120. ">Tabatabaei 2013</a>) </p> </li> </ul> </p> </section> </section> <section id="CD000249-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>Please see <a href="#CD000249-fig-0002">Figure 2</a> and <a href="#CD000249-fig-0003">Figure 3</a> for summaries of the risk of bias for the included studies. </p> <div class="figure" id="CD000249-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD000249-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000249-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD000249-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD000249-sec-0070"> <h4 class="title">Allocation</h4> <p>Nine studies were rated as being at low risk of selection bias related to sequence generation, as they used computer randomization or a random numbers table. The other four studies did not describe the method used and were rated at unclear risk of this bias. </p> <p>Six studies were at low risk of selection bias related to allocation concealment. Seven studies did not describe the method used, and were at unclear risk of allocation bias. </p> </section> <section id="CD000249-sec-0071"> <h4 class="title">Blinding</h4> <p>We did not consider that blinding was likely to influence findings for the primary review outcome (MBL), where this was measured by the objective alkaline haematin method; however, where women used the PBAC, knowledge of their treatment may have influenced their assessment of blood loss. In addition, for adverse effects and subjective secondary outcomes (such as quality of life), blinding status could also potentially affect findings. </p> <p>Six studies were deemed to be at low risk of this bias. Two studies did not describe the method used, so were deemed to be at unclear risk of detection bias. Five studies were deemed to be at high risk of this bias. </p> </section> <section id="CD000249-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>Seven studies analyzed all or most (&gt; 95%) of the women randomized and we judged them to be at low risk of attrition bias. Three studies were at unclear risk of attrition bias. Three studies were at high risk of attrition bias. </p> </section> <section id="CD000249-sec-0073"> <h4 class="title">Selective reporting</h4> <p>We rated most studies as at low risk of selective reporting bias. However, the abstract of <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> only reported results where significant differences were seen between experimental and control groups, potentially leading to overly‐optimistic conclusions; this trial was reported as having a high risk of reporting bias. </p> </section> <section id="CD000249-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>We found no potential sources of within‐study bias in 11 studies. Two studies were thought to be at unclear risk of within‐study bias: <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>, as baseline factors were only reported for women who completed the study (therefore, baseline comparability is unknown); <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>, due to imbalances between the two groups at baseline. </p> </section> </section> <section id="CD000249-sec-0075"> <h3 class="title" id="CD000249-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD000249-tbl-0001"><b>Summary of findings for the main comparison</b> Antifibrinolytics compared to no treatment or placebo for heavy menstrual bleeding</a>; <a href="./full#CD000249-tbl-0002"><b>Summary of findings 2</b> Antifibrinolytics compared to progestogens for heavy menstrual bleeding</a>; <a href="./full#CD000249-tbl-0003"><b>Summary of findings 3</b> Antifibrinolytics compared to NSAIDs for heavy menstrual bleeding</a>; <a href="./full#CD000249-tbl-0004"><b>Summary of findings 4</b> Antifibrinolytics compared to ethamsylate for heavy menstrual bleeding</a>; <a href="./full#CD000249-tbl-0005"><b>Summary of findings 5</b> Antifibrinolytics compared to herbal medicines for heavy menstrual bleeding</a>; <a href="./full#CD000249-tbl-0006"><b>Summary of findings 6</b> Antifibrinolytics compared to levonorgestrel intrauterine system</a> </p> <section id="CD000249-sec-0076"> <h4 class="title">1. Antifibrinolytics versus placebo or no treatment</h4> <p>There were no trials of antifibrinolytic therapy versus no treatment as the control group. Four studies compared antifibrinolytic treatment with placebo: <a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a>; <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>; <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; and <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> (565 participants). Please see <a href="./full#CD000249-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD000249-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD000249-sec-0078"> <h6 class="title">1.1 Menstrual blood loss</h6> <p>Four trials with 565 participants reported this outcome, using measurements of menstrual blood loss (MBL). There is evidence that tranexamic acid was associated with less MBL, compared to placebo (MD −53.20 mL per cycle, 95% CI −62.70 to −43.70; P &lt; 0.00001, I² = 8%; 4 RCTs, participants = 565; low‐quality evidence; <a href="./references#CD000249-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD000249-sec-0079"> <h6 class="title">1.2 Improvement in HMB</h6> <p>Three RCTs reported rates of improvement, measured either subjectively (<a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a>) or objectively (<a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>). Rates of improvement were higher in the antifibrinolytic treatment group (RR 3.34, 95% CI 1.84 to 6.09; P &lt; 0.0001, I² = 32%; 3 RCTs, participants = 271; moderate‐quality evidence; <a href="./references#CD000249-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD000249-sec-0080"> <h6 class="title">1.3 Thromboembolic events</h6> <p>Only two of the studies reported this outcome. <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a> reported that there were no thrombotic or thromboembolic adverse effects in either group. One participant from the placebo group in <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> had a deep venous thrombosis during the trial; no thrombotic events were reported in their antifibrinolytic treatment group. Unfortunately neither study was powered for this outcome. </p> </section> </section> <section id="CD000249-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD000249-sec-0082"> <h6 class="title">1.4 Quality of life</h6> <p>Two RCTs reported this outcome, using the Menorrhagia Impact Questionnaire. Tranexamic acid was associated with an improvement in quality of life with regard to: social/leisure activities (MD 0.52 points per cycle, 95% CI 0.31 to 0.74; P &lt; 0.00001, I² = 0%; 2 RCTs, participants = 365; moderate‐quality evidence); physical activities (MD 0.55 points per cycle, 95% CI 0.34 to 0.77; P &lt; 0.00001, I² = 0%; 2 RCTs, participants = 365; moderate‐quality evidence); and work in or outside the home (MD 0.55 points per cycle, 95% CI 0.30 to 0.80; P &lt; 0.0001; 1 RCT, participants = 187; moderate‐quality evidence; <a href="./references#CD000249-fig-0006" title="">Analysis 1.3</a>). We calculated SDs for one of the studies from what appear to be SEs (<a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>), as noted in the Methods section. </p> </section> <section id="CD000249-sec-0083"> <h6 class="title">1.5 Adverse events (other than thromboembolic events)</h6> <p>There was insufficient evidence to determine whether there is a difference between the groups in the overall rate of adverse events (RR 1.05, 95% CI 0.93 to 1.18; P = 0.46; 1 RCT, participants = 297; low‐quality evidence; <a href="./references#CD000249-fig-0007" title="">Analysis 1.4</a>). </p> <p>Nor was there any clear evidence of a difference in rates of any specific adverse event, though confidence intervals were wide. Events reported in the included studies were as follows: gastrointestinal adverse effects, headache, uterine cancer, vaginal dryness, dysmenorrhoea, viral upper respiratory tract infection, arthralgia, myalgia, nasal congestion, sinusitis, multiple allergies, throat irritation, anaemia, abdominal discomfort, cough, insomnia, dyspepsia, migraine. </p> </section> </section> </section> <section id="CD000249-sec-0084"> <h4 class="title">2. Antifibrinolytics versus progestogens</h4> <p>Four RCTs compared antifibrinolytic treatment to oral luteal phase progestogens (during the second half of the menstrual cycle) (<a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>); and two RCTs compared antifibrinolytic treatment to oral long‐course (i.e. from day 5 of the menstrual cycle) progestogens (<a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>). </p> <section id="CD000249-sec-0085"> <h5 class="title">Primary outcomes</h5> <section id="CD000249-sec-0086"> <h6 class="title">2.1 Menstrual blood loss</h6> <p>Six RCTs reported this outcome. One used an objective measure (<a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>, alkaline haematin method). Five used subjective measures (<a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>, PBAC). </p> </section> <section id="CD000249-sec-0087"> <h6 class="title">2.1.1 Objective assessment of mean blood loss</h6> <p><a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> compared antifibrinolytic treatment versus luteal phase NET, assessed using the alkaline haematin method. Antifibrinolytic treatment was associated with less mean blood loss than NET: mean value (SD) after treatment with antifibrinolytic treatment was 97 (SD 89); mean value after treatment with NET was 208 (SD 135; <a href="#CD000249-tbl-0007">Table 1</a>). </p> <div class="table" id="CD000249-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Antifibrinolytic agent vs control: menstrual blood loss</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Intervention group</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finding (e.g. P value for difference between groups, as reported in primary study)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Result (mean (SD))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Result (mean (SD))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>TXA vs progestogens or NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PBAC score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>TXA 3 g daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>204.4 (SD 255.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norethisterone 10 mg daily (luteal phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298.7 (SD 141.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mefenamic acid 1.5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>278.3 (SD 164.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA vs luteal phase MPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean loss by alkaline haematin method (end score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA 4 g daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (SD 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norethisterone (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208 (SD 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.001</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD000249-sec-0088"> <h6 class="title">2.1.2 Subjective assessment of blood loss</h6> <p>Five studies measured blood loss by the PBAC tool, two of which measured long‐course progestogens (for 20 to 25 days of the menstrual cycle, <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>); the others measured luteal phase progestogen (<a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>). Data from <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> could not be pooled in the forest plot because it was skewed; the author reported that there is evidence of less blood loss with antifibrinolytic treatment, compared to NET (mean PBAC with TXA was 204.4 (SD 255.7); mean PBAC with NET was 298.7 (SD 141.3); participants = 112; <a href="#CD000249-tbl-0007">Table 1</a>). </p> <p>For the remaining trials, antifibrinolytic treatment was not associated with an improvement in MBL compared to either luteal phase progestogen or long‐course progestogen (MD −12.22 points per cycle, 95% CI −30.80 to 6.36; very low quality evidence; <a href="./references#CD000249-fig-0008" title="">Analysis 2.1</a>). </p> </section> <section id="CD000249-sec-0089"> <h6 class="title">2.2 Improvement in HMB</h6> <p>Four studies measuring luteal‐phase progestogens reported this outcome (<a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>). Overall, antifibrinolytic treatment was associated with higher rates of improvement (RR 1.66, 95% CI 1.34 to 2.05; P &lt; 0.00001, I² = 0%; 4 RCTs, participants = 328; low‐quality evidence; <a href="./references#CD000249-fig-0011" title="">Analysis 2.4</a>). </p> <p><a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>, which measured long course progestogens (commencing on day 5 of the menstrual cycle), also found higher rates of improvement compared to baseline (RR 1.32, 95% CI 1.08 to 1.61; P = 0.006; 1 RCT, participants = 94; low‐quality evidence; <a href="./references#CD000249-fig-0011" title="">Analysis 2.4</a>). </p> </section> <section id="CD000249-sec-0090"> <h6 class="title">2.3 Thromboembolic events</h6> <p>No studies reported this outcome.</p> </section> </section> <section id="CD000249-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD000249-sec-0092"> <h6 class="title">2.4 Quality of life</h6> <p>Four studies reported this outcome in a usable form (<a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>). <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> also assessed quality of life, using a 6‐item questionnaire, but the data were not in a usable form. </p> <p>There was no evidence of any differences in the quality of life domains measured in <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> between antifibrinolytic treatment and NET (see <a href="./references#CD000249-fig-0012" title="">Analysis 2.5</a>); these domains included general health, abdominal pain, limitation of social activities and sex life. </p> <p>Neither <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> nor <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> found any evidence of differences in quality of life measures between antifibrinolytic treatment and long‐course progestogens (days 5 to 26 of the menstrual cycle), using the SF‐36 or WHOQOL‐BREF TR respectively. See <a href="./references#CD000249-fig-0013" title="">Analysis 2.6</a>. </p> <p>Two trials assessed a more general, HMB‐specific quality of life measure (<a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>). These studies were pooled using a standardized mean difference analysis. There was insufficient evidence to determine whether there is a difference in the summary effect measure (standard mean difference −0.06, 95% CI −0.32 to 0.21, P = 0.67, 2 RCTs, participants = 218, low‐quality evidence). See <a href="./references#CD000249-fig-0014" title="">Analysis 2.7</a>. </p> </section> <section id="CD000249-sec-0093"> <h6 class="title">2.5 Adverse events (other than thromboembolic events)</h6> <p>Four studies reported overall adverse event rates (<a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a>; <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>; <a href="./references#CD000249-bbs2-0010" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. ">Kriplani 2006</a>; <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a>). The evidence suggested that antifibrinolytic treatment is associated with a lower rate of adverse events than progestogens (RR 0.66, 95% CI 0.46 to 0.94; P = 0.02, I² = 28%; 4 RCTs, participants = 349; low‐quality evidence; <a href="./references#CD000249-fig-0015" title="">Analysis 2.8</a>). The most common events in the antifibrinolytic treatment groups were gastrointestinal effects, vertigo and headache, whilst the most common in the progestogen groups were bleeding, headaches, breast tenderness, and gastrointestinal effects. </p> <p>Two participants withdrew from <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> due to side effects: one from the antifibrinolytic treatment group because of headaches, and one from the NET group due to an elevation in alanine transaminase. </p> <p>Six participants in <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a>'s NET group withdrew due to side effects: three due to headache, two due to bloating, and one due to weight gain. Ten participants in this study's antifibrinolytic treatment group withdrew due to side effects: five due to headache; three, nausea; one, weight gain; and one, a rash. </p> <p>There was no clear evidence of a difference in rates of any specific adverse event, though confidence intervals were wide. Events reported in the included studies were as follows: gastrointestinal effects, headache, dysmenorrhoea, weight gain, allergic reaction, giddiness, intermenstrual bleeding, breast tenderness, mood changes, rash, muscle pain, bloating, nausea, spotting, excess hair growth, and depression. See <a href="./references#CD000249-fig-0015" title="">Analysis 2.8</a>. </p> </section> </section> </section> <section id="CD000249-sec-0094"> <h4 class="title">3. Comparison of antifibrinolytic therapy versus other medical (non‐surgical) treatments: non‐steroidal anti‐inflammatory drugs (NSAIDs) </h4> <p>Two trials compared antifibrinolytic treatment to NSAIDS: <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a> compared 4 g TXA/day to mefenamic acid (MFA) 500 mg TDS on days 1 to 5, while <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> compared 3 g TXA/day to 1.5 g MFA/day on days 1 to 5. </p> <section id="CD000249-sec-0095"> <h5 class="title">Primary outcomes</h5> <section id="CD000249-sec-0096"> <h6 class="title">3.1 Menstrual blood loss</h6> <p>Antifibrinolytic treatment was associated with less MBL, compared to NSAIDs (MD −73.00 mL per cycle, 95% CI −123.35 to −22.65; P = 0.004; 1 RCT, participants = 49; low‐quality evidence; <a href="./references#CD000249-fig-0016" title="">Analysis 3.1</a>). </p> </section> <section id="CD000249-sec-0097"> <h6 class="title">3.2 Improvement in HMB</h6> <p>There was evidence of a difference between the groups when antifibrinolytic treatment was compared to NSAIDs (RR 1.43, 95% CI 1.18 to 1.74; P = 0.0003; 2 RCTs, participants = 161; low‐quality evidence; <a href="./references#CD000249-fig-0017" title="">Analysis 3.2</a>). </p> </section> <section id="CD000249-sec-0098"> <h6 class="title">3.3 Thromboembolic events</h6> <p>No studies reported this outcome.</p> </section> </section> <section id="CD000249-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD000249-sec-0100"> <h6 class="title">3.4 Quality of life</h6> <p>Whilst <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> assessed quality of life using the Menorrhagia Impact Questionnaire, no quantitative data were provided for analysis. </p> </section> <section id="CD000249-sec-0101"> <h6 class="title">3.5 Adverse events (other than thromboembolic events)</h6> <p>One trial measured adverse events (<a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>). The authors did not find any evidence of a difference in the occurrence of headache and dizziness, muscle pain, or dysmenorrhoea between the antifibrinolytic treatment and NSAID groups (see <a href="./references#CD000249-fig-0018" title="">Analysis 3.3</a>). </p> </section> </section> </section> <section id="CD000249-sec-0102"> <h4 class="title">4. Comparison of antifibrinolytic therapy versus other medical (non‐surgical) treatments: ethamsylate </h4> <p>There was only one study that compared antifibrinolytic treatment to ethamsylate: <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a> compared 4 g TXA/day to ethamsylate 500 mg four times daily on days 1 to 5. </p> <section id="CD000249-sec-0103"> <h5 class="title">Primary outcomes</h5> <section id="CD000249-sec-0104"> <h6 class="title">4.1 Menstrual blood loss</h6> <p><a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a> used the alkaline haematin method to quantify MBL. Antifibrinolytic treatment was associated with less MBL, when compared to ethamsylate (MD −100.00 mL per cycle, 95% CI −141.82 to −58.18; P &lt; 0.00001; 1 RCT, participants = 53; low‐quality evidence; <a href="./references#CD000249-fig-0019" title="">Analysis 4.1</a>). </p> </section> <section id="CD000249-sec-0105"> <h6 class="title">4.2 Improvement in HMB</h6> <p><a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a> asked women whether or not their MBL during treatment was less, the same, or more. There was no evidence of a difference between the groups in the rates of women reporting less bleeding when antifibrinolytic treatment was compared to ethamsylate (RR 1.56, 95% CI 0.95 to 2.55; P = 0.08; 1 RCT, participants = 53; very low quality evidence; <a href="./references#CD000249-fig-0020" title="">Analysis 4.2</a>). </p> </section> <section id="CD000249-sec-0106"> <h6 class="title">4.3 Thromboembolic events</h6> <p>The study did not report this outcome.</p> </section> </section> <section id="CD000249-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD000249-sec-0108"> <h6 class="title">4.4 Quality of life</h6> <p>The study did not report this outcome.</p> </section> <section id="CD000249-sec-0109"> <h6 class="title">4.5 Adverse events (other than thromboembolic events)</h6> <p>There was no evidence of a difference in the number of women who withdrew from the antifibrinolytic treatment or ethamsylate groups between the groups when antifibrinolytic treatment was compared to ethamsylate (RR 0.78, 95% CI 0.19 to 3.15; P = 0.73; 1 RCT, participants = 53; very low quality evidence; <a href="./references#CD000249-fig-0021" title="">Analysis 4.3</a>). </p> </section> </section> </section> <section id="CD000249-sec-0110"> <h4 class="title">5. Comparison of antifibrinolytic therapy versus other medical (non‐surgical) treatments: herbal remedies (Safoof Habis and Punica granatum) </h4> <p>One study compared antifibrinolytic treatment to Safoof Habis: <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> compared 3 g TXA/day to Safoof Habis 5 g powder BD, on days 1 to 5. As noted previously, Safoof Habis is a Unani formulation made up of: Teen Ahmer (silicate of alumina and iron oxide); Sange Jarahat (hydrated magnesium silicate); and Raal Sufaid (<i>Vateria indica</i> Linn, which is a species of plant in the <i>Disterocarpaceae</i> family, endemic to India), in equal parts. </p> <p>One trial compared antifibrinolytic treatment to <i>Punica granatum</i> (commonly known as pomegranate flower) (<a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>). </p> <section id="CD000249-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD000249-sec-0112"> <h6 class="title">5.1 Menstrual blood loss</h6> <p><a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> used a menstrual pictogram (a modified PBAC) to ascertain a subjective assessment of MBL, while <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a> used PBAC. </p> <p>There was evidence that antifibrinolytic treatment was associated with less MBL after three months' treatment, compared to these herbal remedies (MD −23.90 points per cycle, 95% CI −31.92 to −15.88; P &lt; 0.00001; 2 RCTs, participants = 121; low‐quality evidence; <a href="./references#CD000249-fig-0022" title="">Analysis 5.1</a>). </p> <p>The baseline values of MBL in <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> appeared different between randomized groups (without reaching statistical significance (P = 0.107)). Hence, the mean reduction (difference between baseline and later measurement) is considered a more reliable way to compare menstrual bleeding in participants, as it adjusts for different baseline levels. </p> <p>Antifibrinolytic treatment was associated with less blood loss after 3 months' treatment (based on the PBAC) than Safoof Habis (MD −24.00 points per cycle, 95% CI −32.15 to −15.85; 1 RCT, participants = 45; low‐quality evidence). Antifibrinolytic treatment is associated with sustained decreased MBL three months after the end of the treatment period, compared to Safoof Habis (MD −10.40 points per cycle, 95% CI −19.20 to −1.60; P = 0.02; 1 RCT, participants = 45; low‐quality evidence; <a href="./references#CD000249-fig-0022" title="">Analysis 5.1</a>). </p> <p><a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a> utilized PBAC to compare mean blood loss between the tranexamic acid and pomegranate flower groups, and their baseline (pre‐treatment) mean blood loss. Both groups showed evidence of a reduction in mean blood loss from baseline, compared to three months of treatment: the antifibrinolytic treatment group's mean reduction in blood loss was 161.31 (PBAC score) and the pomegranate flower group's mean reduction in blood loss was 140.31 (PBAC score). However, there was no evidence of a difference between the groups. </p> </section> <section id="CD000249-sec-0113"> <h6 class="title">5.2 Improvement in HMB</h6> <p>No studies reported this outcome.</p> </section> <section id="CD000249-sec-0114"> <h6 class="title">5.3 Thromboembolic events</h6> <p>No studies reported this outcome.</p> </section> </section> <section id="CD000249-sec-0115"> <h5 class="title">Secondary outcomes</h5> <section id="CD000249-sec-0116"> <h6 class="title">5.4 Quality of life</h6> <p><a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a> used an Iranian version of both the Menorrhagia Impact Questionnaire (MIQ) and the SF‐36 when assessing quality of life. The authors found no evidence of a difference between the antifibrinolytic treatment and progestogen groups when using the MIQ. Of the eight domains of the SF‐36, the only finding was of more improvement in general health (from before to after treatment) amongst the antifibrinolytic treatment group (compared to the progestogen group) (MD 10.30 points per cycle, 95% CI 2.41 to 18.19; P = 0.01; 1 RCT, participants = 76; low‐quality evidence; <a href="./references#CD000249-fig-0023" title="">Analysis 5.2</a>). Of note: there was no difference between post‐treatment SF‐36 scores in the antifibrinolytic treatment and progestogen groups. </p> </section> <section id="CD000249-sec-0117"> <h6 class="title">5.5 Adverse events (other than thromboembolic events)</h6> <p>No studies reported this outcome.</p> </section> </section> </section> <section id="CD000249-sec-0118"> <h4 class="title">6. Antifibrinolytics versus levonorgestrel intrauterine system (LIUS)</h4> <p>One study compared antifibrinolytic treatment levonorgestrel intrauterine system (LIUS): <a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> (62 participants). Please see <a href="./full#CD000249-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD000249-sec-0119"> <h5 class="title">Primary outcomes</h5> <section id="CD000249-sec-0120"> <h6 class="title">6.1 Menstrual blood loss</h6> <p>The authors used median difference in PBAC scores (from baseline) to measure MBL. There is evidence that LIUS was associated with less MBL, compared to TXA (median difference in PBAC score for LIUS −252, compared to −126.5 for TXA group; P = 0.002; 1 RCT, participants = 42; very low quality evidence; <a href="./references#CD000249-fig-0025" title="">Analysis 6.1</a>). </p> <p>Measuring the percentage difference in PBAC scores from baseline to six months of treatment revealed that the TXA group had an average percentage difference of −60.8 PBAC score (IQR 34.9, very low quality evidence), whilst the LIUS group had a −85.8 percentage difference in PBAC score after six months' treatment (IQR 20.3, very low quality evidence). </p> <p>This means that if 850 per 1000 women taking LIUS improved their PBAC score to be less than 100, 364 of 1000 taking TXA did (RR 0.43, 95% CI 0.24 to 0.77; very low quality evidence). </p> </section> <section id="CD000249-sec-0121"> <h6 class="title">6.2 Improvement in HMB</h6> <p>The authors used percentage difference in PBAC scores (from baseline to three months after treatment) to judge the improvement in menstrual bleeding. Rates of improvement were higher in the LIUS group (median PBAC score in LIUS group −85.8, compared to −60.8 for TXA group; 1 RCT, participants = 42; very low quality evidence; <a href="./references#CD000249-fig-0026" title="">Analysis 6.2</a>). </p> <p>The authors also used the number of patients in each group reporting a PBAC score of less than 100 after three months' treatment as a measurement of their improvement in menstrual bleeding. Rates of improvement were higher in the LIUS group (RR 0.43, 95% CI 0.24 to 0.77; P = 0.004; 1 RCT, participants = 42; very low quality evidence; <a href="./references#CD000249-fig-0027" title="">Analysis 6.3</a>). </p> </section> <section id="CD000249-sec-0122"> <h6 class="title">6.3 Thromboembolic events</h6> <p>This study did not report thromboembolic events.</p> </section> </section> <section id="CD000249-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD000249-sec-0124"> <h6 class="title">6.4 Quality of life</h6> <p><a href="./references#CD000249-bbs2-0009" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonogestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. ">Kiseli 2016</a> reported this outcome using the World Health Organization's Quality of Life‐Short Form, Turkish version (WHOQOL‐BREF TR). As can be seen in <a href="./references#CD000249-fig-0028" title="">Analysis 6.4</a>, there was no evidence of differences in quality‐of‐life parameters in any domain measured. </p> </section> <section id="CD000249-sec-0125"> <h6 class="title">6.5 Adverse events (other than thromboembolic events)</h6> <p>There was no evidence of a difference between the groups in the overall rate of adverse events (OR 0.83, 95% CI 0.25 to 2.80; P = 0.77; 1 RCT, participants = 42; very low quality evidence). Nor was there any clear evidence of a difference in rates of any specific adverse event, though confidence intervals were wide. Events reported in the included studies were as follows: headache, bloating, nausea, weight gain, rash, spotting, excess hair growth, breast tenderness, and depression. See <a href="./references#CD000249-fig-0029" title="">Analysis 6.5</a>. </p> </section> </section> </section> <section id="CD000249-sec-0126"> <h4 class="title">Other analyses</h4> <p>Sensitivity analysis using a random‐effects effect model did not substantially influence any of our findings. </p> <p>There were insufficient studies to construct a funnel plot.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000249-sec-0127" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000249-sec-0127"></div> <section id="CD000249-sec-0128"> <h3 class="title" id="CD000249-sec-0128">Summary of main results</h3> <p>This Cochrane review evaluated the effectiveness and safety of antifibrinolytic medications (tranexamic acid and its alternatives, such as pro‐drug Kabi) in the medical management of heavy menstrual bleeding. Four studies compared TXA or Kabi to placebo, and six compared TXA to progestogens. There were few studies for the other comparisons: two compared TXA to NSAIDs (mefenamic acid), one compared TXA to ethamsylate, two to different herbal remedies, and one to levonorgestrel IUS (LIUS). Hence, there is insufficient evidence for these latter comparisons. </p> <p>No studies were found that compared antifibrinolytic treatment to the combined oral contraceptive pill (COCP). </p> <p>On the available evidence, antifibrinolytics appear to be more effective than placebo, short courses of luteal phase oral progestogens, NSAIDs, ethamsylate or herbal remedies in reducing HMB . There is a 40% to 50% reduction from baseline in MBL for participants treated with tranexamic acid. There is a 25% to 50% reduction from baseline in measured MBL for participants treated with tranexamic acid when compared to other medical therapies. </p> <p>If response to treatment is defined by reduction of MBL to less than 80 mL per cycle, 56% (14/25) of women had their menstrual cycles reduced to below 80 mL per cycle in the only study that provided this information (<a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a>). </p> <p>Antifibrinolytic treatment is more effective than NET (when NET was given during the luteal phase only), but was of similar efficacy when the NET was given throughout the menstrual cycle (i.e. from day 5). There was no evidence of a reduction in MBL with antifibrinolytic treatment, compared to long‐course MPA (when judged by PBAC), but there was when it was compared to three months' treatment with Safoof Habis. </p> <p>Antifibrinolytic treatment reduces HMB in studies where blood loss has been measured, and in studies using self‐reported HMB compared to oral luteal phase progestogens. Antifibrinolytic treatment was not more effective in reducing HMB as reported by the patient compared to placebo, NSAIDs or ethamsylate, although results almost reached statistical significance. There is a strong trend in favour of tranexamic acid and, with additional trials, a difference may be reported. </p> <p>Antifibrinolytic therapy was not associated with reduced MBL compared to luteal phase progestogens. However, antifibrinolytic therapy was associated with a greater improvement in HMB (as perceived by the participants), compared to luteal phase progestogens. The reasons behind this apparent discrepancy could be that women's own perception of their MBL is not particularly well correlated with the actual objective volume of blood lost. <a href="./references#CD000249-bbs2-0052" title="Royal College of Obstetricians and Gynaecologists. Heavy menstrual bleeding. National Institute for Health and Clinical Excellence; 2016 August. ">NICE 2016</a> recognises that, in practical terms, it is women's subjective perception of their MBL that takes precedence over objective, laboratory‐based measures such as the alkaline haematin test. </p> <p>LIUS showed a reduction in mean blood loss compared to antifibrinolytic treatment.</p> <p>The impact of antifibrinolytic treatment on quality of life has been compared with placebo and oral progestogen therapy. Compared to placebo, antifibrinolytic treatment was associated with an improvement in quality of life. </p> <p>Antifibrinolytic treatment improved quality of life in women with HMB more effectively than oral luteal phase progestogens: antifibrinolytic treatment was more effective in reducing flooding/leakage, and improving sex life. There were no differences between antifibrinolytic treatment and oral luteal phase progestogens in general health, abdominal pain, or social activities in women with HMB. <a href="./references#CD000249-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. ">Goshtasebi 2013</a> was the only trial to use the SF‐36 tool to assess quality of life: there was no difference between the antifibrinolytic treatment and MPA groups in regard to quality of life. </p> <p>Apart from four larger studies — <a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>, <a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a>, <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> and <a href="./references#CD000249-bbs2-0013" title="ZhangY , HeF , SunZ , LIS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. ">Zhang 2008</a> — the number of women in the other eight trials was small (&lt; 100 participants). There are some limitations to this evidence: the results are based on very small numbers of participants for all comparisons, and the data for some comparisons are heavily skewed. </p> <p>Women using antifibrinolytics for HMB are likely to be using this treatment long term; any adverse events affecting adherence or safety are particularly important. With respect to the safety of tranexamic acid and alternative medical management of HMB, only five of the included studies reported adverse effects in both treatment groups. There was no evidence of a difference between the groups, but data were too scanty to reach any reliable conclusions about safety. </p> <p><a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a> did not find any thrombotic or thromboembolic adverse effects in either the placebo or antifibrinolytic treatment group. One participant from the placebo group in <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a> had a deep venous thrombosis during the trial; no thrombotic events were reported in their antifibrinolytic treatment group. Neither of these trials was powered to detect this outcome. </p> <p>It was outside the scope of this review's search strategy to collate cohort and case‐controlled studies which might have clarified this point. A noticeable limitation of this review is the short period of treatment in the included trials (mostly three months). </p> </section> <section id="CD000249-sec-0129"> <h3 class="title" id="CD000249-sec-0129">Overall completeness and applicability of evidence</h3> <p>This Cochrane review included 13 studies with data that were relevant to this review question. </p> <p>The participants in these studies were all women who reported heavy menstrual bleeding. This was objectively confirmed using the alkaline haematin method in five studies, and the PBAC in seven studies. In clinical practice, the patient‐perceived HMB may be more practicable in judging which women have troublesome HMB requiring treatment than either the alkaline haematin method or PBAC. </p> <p>Participants in the studies included women aged 15 to 50 years old, with measured or self‐reported ovulatory heavy menstrual bleeding. Hence, the conclusions drawn from these studies may not be representative of women with anovulatory HMB (i.e. during adolescence or around the menopause; or HMB due to conditions associated with anovulation, such as polycystic ovarian syndrome). Therefore, the results of this Cochrane review should be viewed with caution when attempting to extrapolate its conclusions to such patient groups. </p> <p>Where MBL was measured, most studies only included women with MBL of more than 80 mL per cycle. However, 50% of women who self‐report HMB do not have a measured MBL of more than 80 mL. Hence it is unclear whether studies that only included women with MBL of more than 80 mL are relevant for the management of women in clinical practice which relies on self‐reported HMB. Of the studies that used self‐reported MBL, <a href="./references#CD000249-bbs2-0002" title="CallenderST , WarnerGT , CopeE . Treatment of menorrhagia with tranexamic acid. A double blind trial. British Medical Journal1970;4(5729):214‐6. ">Callender 1970</a> reported a 37% decrease in MBL with antifibrinolytic treatment compared to placebo; <a href="./references#CD000249-bbs2-0001" title="BonnarJ , SheppardB . Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ1996;313(7057):579‐82. ">Bonnar 1996</a> reported that antifibrinolytic treatment reduced MBL by 54% compared to no treatment; <a href="./references#CD000249-bbs2-0003" title="EdlundM , AnderssonK , RyboG , LindoffCC , AstedtB , SchoultBV . Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi2161). British Journal of Obstetrics and Gynaecology1995;102(11):913‐7. ">Edlund 1995</a> reported a 33% reduction in MBL with Kabi QDS, and 41% reduction with Kabi BD, both compared to placebo; <a href="./references#CD000249-bbs2-0004" title="FathimaA , SultanaA . Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. European Journal of Integrative Medicine2012;4(3):e315‐22. ">Fathima 2012</a> reported that antifibrinolytic treatment and Safoof Habis were equally effective in reducing MBL — the PBAC score in the antifibrinolytic treatment group improved from 162.37 at baseline to 75.3 over the course of three cycles; and <a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> reported that antifibrinolytic treatment reduced MBL by 45%. </p> </section> <section id="CD000249-sec-0130"> <h3 class="title" id="CD000249-sec-0130">Quality of the evidence</h3> <p>The methodological quality of the evidence varied from very low to moderate. The main limitations were risk of bias (associated with lack of blinding, and poor reporting of study methods), imprecision and inconsistency. See <a href="#CD000249-sec-0128">Summary of main results</a>, <a href="#CD000249-fig-0002">Figure 2</a> and <a href="#CD000249-fig-0003">Figure 3</a> for more details. </p> <p>Classic or modified intention‐to‐treat analysis was performed by only three studies, whilst three performed a priori power calculations (<a href="./references#CD000249-bbs2-0005" title="FreemanEW , LukesA , VanDrieD , MabeyRG , GerstenJ , AdomakoTL . A dose‐response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. American Journal of Obstetrics and Gynecology2011;205(4):319.e1‐319.e7. ">Freeman 2011</a>; <a href="./references#CD000249-bbs2-0007" title="GoshtasebiA , MazariZ , Behboudi GandevaniS , NaseriM . Anti‐hemorrhagic activity of Punica granatum L. flower (Persian Golnar) against heavy menstrual bleeding of endometrial origin: a double‐blind, radomized controlled trial. Medical Journal of the Islamic Republic of Iran2015;29:199. ">Goshtasebi 2015</a>; <a href="./references#CD000249-bbs2-0011" title="LukesAS , MooreKA , MuseKN , GerstenJK , HechtBR , EdlundM , et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstetrics and Gynecology2010;116(4):865‐75. ">Lukes 2010</a>). </p> <p>For a number of outcomes, only one trial reported data; lack of power together with major study limitations meant that the quality of the evidence for many of these outcomes was very low. In addition, where studies were not blinded and PBAC was used to measure the primary bleeding outcome or adverse events were experienced, the participants' knowledge of their treatment was likely to have influenced their assessment of their bleeding and adverse events. Hence, these findings should be considered tentative. No outcome results were supported by high‐quality evidence. A few had moderate‐quality evidence, but most had either low‐quality or very low quality evidence. </p> </section> <section id="CD000249-sec-0131"> <h3 class="title" id="CD000249-sec-0131">Potential biases in the review process</h3> <p>We attempted to identify and include all relevant studies through the standardized method of identifying studies, but it is possible we may have missed some studies. Not all trial authors responded to our requests for more information; we are unsure whether our requests always reached the author and so imputation was used for some data. </p> <p>The authors attempted to minimise potential biases in the review process by undertaking duplicate selection of studies, duplicate data extraction, and duplicate assessment of risk of bias. Where there were disagreements, the authors resolved these through discussion and reaching consensus, if necessary with the help of a third author. </p> </section> <section id="CD000249-sec-0132"> <h3 class="title" id="CD000249-sec-0132">Agreements and disagreements with other studies or reviews</h3> <p>Current practice in managing HMB varies widely, both between and within countries. The United Kingdom's National Institute for Health and Clinical Excellence (NICE) guideline regarding management of HMB recommends the following medical managements, in order of preference, for women with no suspected structural/histological abnormalities underlying their HMB: levonorgestrel intrauterine system (LIUS); TXA, NSAIDs or COCP; NET (days 5 to 26 of the menstrual cycle); or injected long‐acting progestogens (<a href="./references#CD000249-bbs2-0052" title="Royal College of Obstetricians and Gynaecologists. Heavy menstrual bleeding. National Institute for Health and Clinical Excellence; 2016 August. ">NICE 2016</a>). </p> <p>The Society of Obstetricians and Gynaecologists of Canada (SCOG) outlines the following medical treatments for HMB: non‐hormonal (NSAIDs, antifibrinolytic treatment); and hormonal (COCP, levonorgestrel intrauterine system, oral progestins, Depot‐MPA, danazol, and GnRH‐agonists). Unfortunately they do not provide any clear guidance as to which is preferable, other than broad statements recommending that patients' contraceptive needs and medical co‐morbidities should be taken into account (<a href="./references#CD000249-bbs2-0054" title="SinghS , BestC , DunnS , LyelandN , WolfmanWL . Medical treatment. Journal of Obstetrics and Gynaecology Canada2013;35(5):S12‐7. ">Singh 2013</a>). Hence our findings support current recommendations from both NICE and SCOG regarding the efficacy of antifibrinolytic treatment in managing HMB. </p> <p><a href="./references#CD000249-bbs2-0046" title="LumsdenMA , WedisingheL . Tranexamic acid for heavy menstrual bleeding. Expert Opinion on Pharmacotherapy2011;12(13):2089‐95. ">Lumsden 2011</a> is a succinct review of the use of TXA in HMB in clinical practice. The authors conclude that TXA is particularly useful for the management of HMB in women who either desire pregnancy immediately or for whom hormonal treatment is inappropriate. They describe TXA as being a well‐tolerated and cost‐effective drug that reduces MBL by 34% to 59%, whilst improving health‐related quality of life in women with HMB. </p> <p>A previous systematic review investigated the efficacy of tranexamic acid in treating heavy menstrual bleeding (<a href="./references#CD000249-bbs2-0050" title="NaoulouB , TsaiM . Efficacy of tranexamic acid in the treatment of idiopathic and non‐functional heavy menstrual bleeding: a systematic review. Acta Obstetricia et Gynecologica Scandinavica2012;91(5):529‐37. ">Naoulou 2012</a>). In line with this current review, the authors concluded that tranexamic acid is effective and safe in management HMB: their results showed a 34% to 54% reduction in either self‐reported or measured MBL with antifibrinolytic treatment. </p> <p>Another systematic review compared RCTs of non‐surgical management of HMB (<a href="./references#CD000249-bbs2-0048" title="MattesonK , RahnD , WheelerT , CasianoE , SiddiquiN , HarvieH , et al. Nonsurgical management of heavy menstrual bleeding. Obstetrics and Gynecology2013;121(3):632‐43. ">Matteson 2013</a>), which was presumed to be secondary to endometrial dysfunction and anovulation. The non‐surgical methods in the comparison included: the LIUS, combined OCP, progestins, NSAIDs, and anti‐fibrinolytics. The authors concluded that these management options' efficacies (listed from most to least efficacious) were: LIUS (71% to 95% reduction in menstrual bleeding); COCP (35% to 69% reduction); extended cycle oral progestogens (87% reduction); TXA (26% to 54% reduction); NSAIDs (10% to 52% reduction). Of note: progestins used only during the luteal phase (e.g. days 15 to 26) showed a 20% increase to 67% reduction in menstrual bleeding. Our review has found antifibrinolytic treatment's efficacy to be at the higher end of their range. </p> <p><a href="./references#CD000249-bbs2-0040" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonogestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368(2):128‐37. ">Gupta 2013</a> performed a pragmatic randomized trial, comparing LIUS with 'usual medical treatment', including tranexamic acid, mefenamic acid, COCP and progesterone‐only pills. Whilst all groups showed evidence of a reduction in MBL, the improvement in self‐reported MBL was greater in the LIUS group. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000249-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (PRISMA chart)." data-id="CD000249-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (PRISMA chart).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD000249-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD000249-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antifibrinolytic agent versus placebo, Outcome 1 Menstrual blood loss: mean loss." data-id="CD000249-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antifibrinolytic agent versus placebo, Outcome 1 Menstrual blood loss: mean loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antifibrinolytic agent versus placebo, Outcome 2 Menstrual blood loss: improvement rates." data-id="CD000249-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antifibrinolytic agent versus placebo, Outcome 2 Menstrual blood loss: improvement rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antifibrinolytic agent versus placebo, Outcome 3 Quality of life scores (change from baseline)." data-id="CD000249-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antifibrinolytic agent versus placebo, Outcome 3 Quality of life scores (change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antifibrinolytic agent versus placebo, Outcome 4 Adverse events." data-id="CD000249-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antifibrinolytic agent versus placebo, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 1 Menstrual blood loss: mean PBAC score." data-id="CD000249-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 1 Menstrual blood loss: mean PBAC score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0009"> <p> <div class="table" id="CD000249-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (NET)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (NET)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR (NET)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>After 6 months Rx</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kiseli 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA vs. NET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐125.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.002</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 2 Median difference in PBAC score. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0009">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000249-fig-0010"> <p> <div class="table" id="CD000249-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>median (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (NET)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>median (NET)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR(NET)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>After 6 months Rx</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kiseli 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA vs. NET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐60.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐53.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 3 Percentage difference in PBAC scores. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0010">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000249-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 4 Menstrual blood loss: improvement rates." data-id="CD000249-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 4 Menstrual blood loss: improvement rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 5 Quality of life ‐ improvement (luteal phase MPA)." data-id="CD000249-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 5 Quality of life ‐ improvement (luteal phase MPA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 6 Quality of life ‐ SF36 (long course MPA)." data-id="CD000249-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 6 Quality of life ‐ SF36 (long course MPA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 7 Quality of life ‐ HMB score." data-id="CD000249-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 7 Quality of life ‐ HMB score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 8 Adverse events (short and long course progestogens)." data-id="CD000249-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Antifibrinolytic agent versus progestogens, Outcome 8 Adverse events (short and long course progestogens). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antifibrinolytic agent versus NSAIDs, Outcome 1 Menstrual blood loss: mean loss." data-id="CD000249-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Antifibrinolytic agent versus NSAIDs, Outcome 1 Menstrual blood loss: mean loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antifibrinolytic agent versus NSAIDs, Outcome 2 Menstrual blood loss: improvement rates." data-id="CD000249-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Antifibrinolytic agent versus NSAIDs, Outcome 2 Menstrual blood loss: improvement rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antifibrinolytic agent versus NSAIDs, Outcome 3 Any adverse events." data-id="CD000249-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Antifibrinolytic agent versus NSAIDs, Outcome 3 Any adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antifibrinolytic agent versus ethamsylate, Outcome 1 Menstrual blood loss: mean loss." data-id="CD000249-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Antifibrinolytic agent versus ethamsylate, Outcome 1 Menstrual blood loss: mean loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antifibrinolytic agent versus ethamsylate, Outcome 2 Menstrual blood loss: improvement rates." data-id="CD000249-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Antifibrinolytic agent versus ethamsylate, Outcome 2 Menstrual blood loss: improvement rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antifibrinolytic agent versus ethamsylate, Outcome 3 Withdrawal from treatment because of adverse events." data-id="CD000249-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Antifibrinolytic agent versus ethamsylate, Outcome 3 Withdrawal from treatment because of adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antifibrinolytic agent versus herbal medicines, Outcome 1 Menstrual blood loss: mean loss." data-id="CD000249-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Antifibrinolytic agent versus herbal medicines, Outcome 1 Menstrual blood loss: mean loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antifibrinolytic agent versus herbal medicines, Outcome 2 Quality of life scores." data-id="CD000249-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Antifibrinolytic agent versus herbal medicines, Outcome 2 Quality of life scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Antifibrinolytic agent versus herbal medicines, Outcome 3 Adverse events." data-id="CD000249-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Antifibrinolytic agent versus herbal medicines, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0025"> <p> <div class="table" id="CD000249-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (LIUS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (LIUS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR (LIUS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>After 6 months Rx</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kiseli 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA vs. LIUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐126.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.002</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 1 Median difference in PBAC score. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0025">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000249-fig-0026"> <p> <div class="table" id="CD000249-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR (TXA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N (LIUS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (LIUS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IQR (LIUS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>After 6 months Rx</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kiseli 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA vs. LIUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐60.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐85.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 2 Percentage difference in PBAC scores. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000249-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 3 Improvement in mean blood loss (PBAC score &lt; 100)." data-id="CD000249-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 3 Improvement in mean blood loss (PBAC score &lt; 100). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 4 Quality of life scores." data-id="CD000249-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 4 Quality of life scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000249-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/urn:x-wiley:14651858:media:CD000249:CD000249-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_t/tCD000249-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 5 Adverse events." data-id="CD000249-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Antifibrinolytic agent versus levonorgestrel intrauterine system, Outcome 5 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/media/CDSR/CD000249/image_n/nCD000249-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000249-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antifibrinolytics compared to no treatment or placebo for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to no treatment or placebo for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with heavy menstrual bleeding<br/> <b>Setting</b> : gynaecology outpatient departments; one study simply said ''clinical sites''<br/> <b>Intervention</b> : antifibrinolytics<br/> <b>Comparison</b>: no treatment or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss<br/> Assessed with: alkaline haematin method<br/> Follow‐up: range 3 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss: mean loss ranged from 206 mL to 252 mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 53.2 mL lower<br/> (62.7 lower to 43.7 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>565<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates<br/> Assessed with a variety of methods<br/> Follow‐up: range 3 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000<br/> (200 to 662) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.34<br/> (1.84 to 6.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>836 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>990 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05 (0.93 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most of these adverse events were mild to moderate in severity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Only one thromboembolic event occurred in the two studies that reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level due to risk of bias (2 of 4 studies with unclear randomization and 1 with unclear allocation concealment and 1 study with high risk of attrition bias) </p> <p><sup>2</sup> Quality downgraded 1 level due to risk of bias (1 very small study with substantial risk of attrition bias) </p> <p><sup>3</sup> Quality downgraded 2 levels due to risk of bias (study had unclear allocation concealment and randomization method) and because of imprecision (single study). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antifibrinolytics compared to no treatment or placebo for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000249-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antifibrinolytics compared to progestogens for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to progestogens for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with heavy menstrual bleeding<br/> <b>Setting</b> : any<br/> <b>Intervention</b> : antifibrinolytics<br/> <b>Comparison</b>: progestogens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogens</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss (overall)<br/> Assessed with: PBAC<sup>11</sup><br/> Follow‐up: range 2 months to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score ranged from 114 to 209 pts</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 12.22 pts lower<br/> (30.8 lower to 6.36 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two additional trials (at low risk of bias) had skewed data and are displayed in Additional Table 1. They both found a significant benefit for TXA. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates (overall)<br/> Assessed with: patient assessment<br/> Follow‐up: range 2 months to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>463 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>701 per 1000 (607 to 833)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.54<br/> (1.31 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>422<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall effect combining short‐ and long‐course progestogens.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> <p>Need to add CI here</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.66 (0.46 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No thromboembolic events were diagnosed in either group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level due to inconsistency between the five trials, possibly linked to different measurement tools </p> <p><sup>2</sup> Quality downgraded further 2 levels due to risk of bias (3 of 5 studies with unclear allocation concealment, 2 of 5 studies had high risk of detection bias and 1 study had a high risk of attrition bias) </p> <p><sup>3</sup> Quality downgraded 2 levels due to risk of bias(high risk of detection and reporting bias) </p> <p><sup>4</sup> Quality downgraded a further level due to imprecision (the study was a single small trial) </p> <p><sup>5</sup> Quality downgraded 2 levels due to risk of bias (both trials at high risk of performance bias and 1 trial at high risk of attrition bias) </p> <p><sup>6</sup> Quality downgraded 2 levels due to risk of bias (3 of 4 studies with high risk of detection bias, 1 study with risk of attrition bias and 1 study with risk of reporting bias) </p> <p><sup>7</sup> Quality downgraded 2 levels due to risk of bias (2 of 3 studies with high risk of detection bias, 1 study at risk of reporting bias) </p> <p><sup>8</sup> Quality downgraded 2 levels due to risk of bias (one study with high risk of performance bias and attrition bias) </p> <p><sup>9</sup> Quality downgraded a further level because of imprecision (single small trial) </p> <p><sup>10</sup> Quality downgraded 2 levels due to risk of bias (2 of 3 studies with unclear allocation concealment, 1 study with unclear attrition bias, 1 study with high risk of selective outcome reporting and 2 studies with unclear 'other' bias) </p> <p><sup>11</sup> Some authors consider 100 points in the Pictorial Blood Assessment Chart (PBAC) equivalent to 80 mL of menstrual blood loss (i.e. heavy menstrual bleeding); some 150 points. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antifibrinolytics compared to progestogens for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000249-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antifibrinolytics compared to NSAIDs for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to NSAIDs for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> all<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss<br/> Assessed with: alkaline haematin method<br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss: mean loss was 148 mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 73 mL lower<br/> (123.35 lower to 22.65 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates<br/> Assessed with: patient questionnaire<br/> Follow‐up: range 2 months to 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>869 per 1000<br/> (717 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.43<br/> (1.18 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>The total number of adverse events per group were not measured. Individual adverse events were uncommon. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>These were not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level for study limitations (I study with unclear risk of selection bias) </p> <p><sup>2</sup> Quality downgraded a further level because of imprecision (single very small study) </p> <p><sup>3</sup> Quality downgraded 2 levels because of study limitations (both studies at high risk of performance bias as women assessed this outcome and knowledge of treatment may have influenced the findings) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antifibrinolytics compared to NSAIDs for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000249-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antifibrinolytics compared to ethamsylate for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to ethamsylate for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> all<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> ethamsylate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ethamsylate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss<br/> Assessed with: alkaline haematin method<br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss: mean loss was 175 mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 100 mL lower<br/> (141.82 lower to 58.18 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement rates<br/> Assessed with: patient assessment<br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1000<br/> (422 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.56<br/> (0.95 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal from treatment because of adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78 (0.19 to 3.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Thromboembolic events were not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 1 level due to risk of bias (single study with unclear allocation concealment) </p> <p><sup>2</sup> Quality downgraded 1 level due to risk of bias (single small study) </p> <p><sup>3</sup> Quality downgraded 2 levels due to risk of bias (single study with unclear allocation concealment and high risk of performance bias) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antifibrinolytics compared to ethamsylate for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000249-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Antifibrinolytics compared to herbal medicines for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antifibrinolytics compared to herbal medicines for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> heavy menstrual bleeding<br/> <b>Setting:</b> all<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> herbal medicines </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with herbal medicines</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss ‐ after 3 months Rx<br/> Assessed with: PBAC<sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score ranged from 51 to 143 pts</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 23.90 pts lower (31.2 lower to 15.88 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One trial assessed a 'unani' formulation vs TXA and the other a pomegranate extract vs TXA </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: mean loss ‐ after 3 months' follow‐up from end of Rx<br/> Assessed with: PBAC<sup>4</sup><br/> Follow‐up: mean 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PBAC score was 71.3 pts</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10.4 pts lower<br/> (19.2 lower to 1.6 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC scores evaluated 3 months after Rx was completed in both groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.25 (0.74 to 6.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>The study did not measure any thromboembolic events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality</b> : our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate — the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quality downgraded 2 levels due to risk of bias (one trial had unclear selection, performance, and attrition bias; the other had unclear attrition and other bias) </p> <p><sup>2</sup> Quality downgraded 1 level due to risk of bias(trial had unclear selection, performance and attrition bias) </p> <p><sup>3</sup> Quality downgraded 1 level because of imprecision (single small study) </p> <p><sup>4</sup>Some authors consider 100 points in the Pictorial Blood Assessment Chart (PBAC) equivalent to 80 mL of menstrual blood loss (i.e. heavy menstrual bleeding); some 150 points. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Antifibrinolytics compared to herbal medicines for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000249-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Antifibrinolytics compared to levonorgestrel intrauterine system</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with levonorgestrel for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> heavy menstrual bleeding </p> <p><b>Settings:</b> all </p> <p><b>Intervention:</b> antifibrinolytics </p> <p><b>Comparison:</b> levonorgestrel intrauterine system (IUS) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel IUS</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with TXA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: median difference in PBAC score ‐ after 6 months Rx</p> <p>Assessed with: PBAC<sup>4</sup> </p> <p>Follow‐up: outcomes measured at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>−252.0 (IQR 124.5) <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>−126.5 (IQR 104.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual blood loss: improvement in mean blood loss (PBAC score &lt; 100)</p> <p>Assessed with: PBAC<sup>4</sup> </p> <p>Follow‐up: outcomes measured at end of treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>850 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000 (204 to 655)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.43 (0.24 to 0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83 (0.25 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thromboembolic events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>The study did not measure any thromboembolic events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IQR:</b> Interquartile Range; <b>OR:</b> Odds Ratio; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unable to calculate 'X per 1000 women', as the data are not in a normal distribution, but are skewed. </p> <p><sup>2</sup> Quality downgraded 2 levels due to the one trial being at high risk of: performance and detection bias; and attrition bias. </p> <p><sup>3</sup> Quality downgraded a further level because of imprecision (single small trial). </p> <p><sup>4</sup>Some authors consider 100 points in the Pictorial Blood Assessment Chart (PBAC) equivalent to 80 mL of menstrual blood loss (i.e. heavy menstrual bleeding); some 150 points. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Antifibrinolytics compared to levonorgestrel intrauterine system</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000249-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Antifibrinolytic agent vs control: menstrual blood loss</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Intervention group</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finding (e.g. P value for difference between groups, as reported in primary study)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Result (mean (SD))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Result (mean (SD))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD000249-bbs2-0008" title="JaisamrarnU , SitavarinS , SuwikromS , KamolpornwijitW . Randomized trial of medical therapies for menorrhagia: clinical efficacy and effect on quality of life. XVIII FIGO World Congress of Gynecology and Obstetrics; 2006 Nov 5‐10; Kuala Lumpur (Malaysia). 2006; Vol. 3:83. ">Jaisamrarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>TXA vs progestogens or NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PBAC score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>TXA 3 g daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>204.4 (SD 255.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norethisterone 10 mg daily (luteal phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298.7 (SD 141.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mefenamic acid 1.5 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>278.3 (SD 164.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000249-bbs2-0012" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics and Gynaecology1995;102(5):401‐6. ">Preston 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA vs luteal phase MPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean loss by alkaline haematin method (end score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA 4 g daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 (SD 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norethisterone (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208 (SD 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.001</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Antifibrinolytic agent vs control: menstrual blood loss</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/full#CD000249-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000249-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antifibrinolytic agent versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss: mean loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐53.20 [‐62.70, ‐43.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Objective assessment of mean loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐53.20 [‐62.70, ‐43.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Menstrual blood loss: improvement rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.34 [1.84, 6.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life scores (change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Limitations in social/leisure activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Limitations in physical activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.34, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Limitations in work in or outside the home</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.30, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Gastrointestinal side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.55, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.82, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Uterine cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.06, 32.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Vaginal dryness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.90, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Viral URTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.58, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.68, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Musculoskeletal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.82, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.72, 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.78, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.77 [0.40, 113.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [0.84, 9.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14 Multiple allergies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.68, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15 Throat irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.22, 4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16 Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.72, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17 Abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.30, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.18 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.28, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.19 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.21, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.20 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.06, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.21 Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.46, 10.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antifibrinolytic agent versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000249-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antifibrinolytic agent versus progestogens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss: mean PBAC score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.22 [‐30.80, 6.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Luteal phase NET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.0 [‐65.54, 15.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long course (20‐25 days) MPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.82 [‐29.73, 12.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Median difference in PBAC score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 After 6 months Rx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Percentage difference in PBAC scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 After 6 months Rx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Menstrual blood loss: improvement rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.31, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Luteal phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.34, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Long course (20 to 25 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.08, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life ‐ improvement (luteal phase MPA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.76, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.68, 5.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Limitation of social activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.85, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Sex life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.99, 9.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life ‐ SF36 (long course MPA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [‐0.67, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Role physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [‐5.63, 13.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Bodily pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐11.61, 6.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐2.49, 12.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐6.62, 9.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐1.76, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Role emotional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐12.47, 11.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐1.07, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Environmental domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐0.17, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Environmental domain ‐ TR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐0.39, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Quality of life ‐ HMB score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.32, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Luteal phase progestogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.35, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Long course progestogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.56, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events (short and long course progestogens) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.52, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.46, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Gastrointestinal events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.22, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.44, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.29, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.31, 13.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.12, 66.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Intermenstrual bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Giddiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.03, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 Mood changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11 Muscle pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.12, 72.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12 Bloating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.31, 24.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.14 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.12, 63.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.15 Spotting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.16 Excess hair growth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.17 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antifibrinolytic agent versus progestogens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000249-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antifibrinolytic agent versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss: mean loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alkaline haematin assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐73.0 [‐123.35, ‐22.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Menstrual blood loss: improvement rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.18, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Headache and dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Muscle pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.12, 70.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Dysmenorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antifibrinolytic agent versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000249-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antifibrinolytic agent versus ethamsylate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss: mean loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐100.0 [‐141.82, ‐58.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Menstrual blood loss: improvement rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.95, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawal from treatment because of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.19, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antifibrinolytic agent versus ethamsylate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000249-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Antifibrinolytic agent versus herbal medicines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss: mean loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mean PBAC score (after 3 months Rx)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.90 [‐31.92, ‐15.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mean PBAC score (3 months after end of Rx)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.40 [‐19.20, ‐1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Change in dysmenorrhoea scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.25, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 MIQ score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.20 [‐1.26, 9.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 SF36: physical function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [‐1.73, 8.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 SF36: role physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐9.87, 12.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 SF36: bodily pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐15.34, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 SF36: general health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.30 [2.41, 18.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 SF36: vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [‐4.88, 9.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 SF36: social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐8.54, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 SF36: role emotional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.5 [‐15.05, 8.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 SF36: mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐3.78, 11.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.74, 6.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Antifibrinolytic agent versus herbal medicines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000249-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antifibrinolytic agent versus levonorgestrel intrauterine system</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Median difference in PBAC score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 After 6 months Rx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Percentage difference in PBAC scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 After 6 months Rx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement in mean blood loss (PBAC score &lt; 100) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.24, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Physical domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.78, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Psychological domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.85, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Social domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐1.55, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Environmental domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐0.06, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Environmental domain TR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.29, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.25, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.34, 8.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Bloating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.36 [0.36, 151.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.11, 74.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.11, 74.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Spotting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 7.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Excess hair growth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 7.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 7.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antifibrinolytic agent versus levonorgestrel intrauterine system</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000249.pub2/references#CD000249-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000249.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000249-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000249-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000249-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD000249-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD000249-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD000249-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD000249-note-0002">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000249\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000249\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000249\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000249\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000249\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000249.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000249.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000249.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000249.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000249.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715631844"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000249.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715631848"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000249.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8bd56bf59371',t:'MTc0MDcxNTYzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 